

Session text above this point is available in the transcript,
available from the Transcript Assistant on the toolbar.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2001085207</u>	A2	20011115	<u>WO 2001-US14796</u>	20010507
<u>WO 2001085207</u>	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>US 20020004041</u>	A1	20020110	<u>US 2001-804584</u>	20010312
<u>AU 2001059624</u>	A	20011120	<u>AU 2001-59624</u>	20010507
PRIORITY APPN. INFO.:			<u>US 2000-565958</u>	A 20000505
			<u>US 2001-804584</u>	A2 20010312
			<u>US 1999-251896</u>	A2 19990219
			<u>WO 2001-US14796</u>	W 20010507

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The authors disclose methodol. for modulating the cellular immune response to a pre-selected antigen, either ex vivo or in vivo, whereby dendritic cell maturation is permitted to occur in the absence (or presence) of effective CD4+ T-cell help. The authors also disclose that phagocytosis by dendritic cells was mediated via β 5-integrin. In one example, the authors demonstrate that an anti-influenza cytotoxic T-cell response was enhanced on incubation of syngeneic T-cells with dendritic cells and apoptotic monocytes infected with influenza A virus. In a second related example, anti-influenza cytotoxic T-cell response was suppressed on incubation of syngeneic CD8+ T-cells with dendritic cells in the absence of T-cell help.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2001:809019 CAPLUS
 DOCUMENT NUMBER: 135:343303
 TITLE: Method for enhancing an **antigen** specific immune response with **OX-40** ligand
 INVENTOR(S): Weinberg, Andrew D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 30 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 6312700</u>	B1	20011106	<u>US 1999-255363</u>	19990223
<u>US 20020054873</u>	A1	20020509	<u>US 2001-946832</u>	20010904
<u>US 7504101</u>	B2	20090317		

US 20070207159
US 7622444

A1 20070906
B2 20091124

US 2006-529956

20060929

PRIORITY APPLN. INFO.:

US 1998-75801P

P 19980224

US 1999-255363

A3 19990223

US 2001-946832

Al 20010904

AB Provided are compns. and methods for enhancing the immune response of a mammal to an **antigen** by engaging the **OX-40** receptor on the surface of T-cells are disclosed, comprising administering to the mammal a compn. comprising a purified **OX-40** receptor binding agent and a pharmaceutically acceptable carrier, wherein said compn. is administered to the mammal such that the **OX-40** receptor binding agent is presented to T-cells of the mammal during or shortly after priming of the T-cells by the **antigen**. Such compns. and methods can be used in immunization and cancer treatment.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing References
 Text

ACCESSION NUMBER: 2001:781079 CAPLUS
DOCUMENT NUMBER: 135:348851
TITLE: Albumin fusion proteins with therapeutic proteins for improved shelf-life
INVENTOR(S): Rosen, Craig A.; Haseltine, William A.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc, USA
SOURCE: PCT Int. Appl., 606 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 90
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2001079444</u>	A2	20011025	<u>WO 2001-US12013</u>	20010412
<u>WO 2001079444</u>	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>AU 2001074809</u>	A	20011020	<u>AU 2001-74809</u>	20010412
<u>CA 2405557</u>	A1	20011025	<u>CA 2001-2405557</u>	20010412
<u>EP 1278544</u>	A2	20030129	<u>EP 2001-941457</u>	20010412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
<u>US 20030125247</u>	A1	20030703	<u>US 2001-833041</u>	20010412
<u>US 6994857</u>	B2	20060207		
<u>US 20030171267</u>	A1	20030911	<u>US 2001-833117</u>	20010412
<u>JP 2003530847</u>	T	20031021	<u>JP 2001-577428</u>	20010412
<u>US 20030199043</u>	A1	20031023	<u>US 2001-832501</u>	20010412
<u>US 20030219875</u>	A1	20031127	<u>US 2001-833118</u>	20010412
<u>US 6905688</u>	B2	20050614		

<u>US 6946134</u>	B1	20050920	<u>US 2001-833111</u>	20010412
<u>EP 1803730</u>	A1	20070704	<u>EP 2006-15131</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 1832599</u>	A2	20070912	<u>EP 2006-76852</u>	20010412
<u>EP 1832599</u>	A3	20071121		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 1983055</u>	A1	20081022	<u>EP 2008-75327</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2067488</u>	A1	20090610	<u>EP 2008-75909</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2206720</u>	A1	20100714	<u>EP 2010-75064</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2213743</u>	A1	20100804	<u>EP 2010-75164</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2216409</u>	A1	20100811	<u>EP 2010-75011</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2236152</u>	A1	20101006	<u>EP 2010-75010</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2267026</u>	A1	20101229	<u>EP 2010-75387</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2275557</u>	A1	20110119	<u>EP 2010-75316</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2295456</u>	A1	20110316	<u>EP 2010-75391</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>EP 2298355</u>	A2	20110323	<u>EP 2010-75375</u>	20010412
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
<u>US 20050100991</u>	A1	20050512	<u>US 2004-932104</u>	20040902
<u>US 20070026013</u>	A1	20070201	<u>US 2004-933523</u>	20040903
<u>US 7507413</u>	B2	20090324		
<u>US 20050244931</u>	A1	20051103	<u>US 2004-967457</u>	20041019
<u>US 20050266532</u>	A1	20051201	<u>US 2005-78663</u>	20050314
<u>US 20070287173</u>	A9	20071213		
<u>US 7507414</u>	B2	20090324		
<u>US 20050266533</u>	A1	20051201	<u>US 2005-78914</u>	20050314
<u>US 7482013</u>	B2	20090127		
<u>US 20080261877</u>	A1	20081023	<u>US 2007-927593</u>	20071029
<u>US 20080267962</u>	A1	20081030	<u>US 2007-927555</u>	20071029
<u>US 20090285816</u>	A9	20091119		
<u>US 20080269125</u>	A1	20081030	<u>US 2007-927602</u>	20071029
<u>US 20080269126</u>	A1	20081030	<u>US 2007-927607</u>	20071029
<u>US 20080269127</u>	A1	20081030	<u>US 2007-927610</u>	20071029
<u>US 20080269128</u>	A1	20081030	<u>US 2007-927617</u>	20071029
<u>US 20080131399</u>	A1	20080605	<u>US 2007-929677</u>	20071030
<u>US 7785599</u>	B2	20100831		
<u>US 20090075880</u>	A1	20090319	<u>US 2008-140228</u>	20080616
<u>US 20090105140</u>	A1	20090423	<u>US 2008-171154</u>	20080710
<u>US 20100189686</u>	A1	20100729	<u>US 2009-365878</u>	20090204
<u>US 20100249026</u>	A1	20100930	<u>US 2010-784345</u>	20100520

PRIORITY APPN. INFO.:

<u>US 2000-229358P</u>	P	20000412
<u>US 2000-199384P</u>	P	20000425
<u>US 2000-256931P</u>	P	20001221
<u>EP 2001-932549</u>	A3	20010412
<u>EP 2001-934875</u>	A3	20010412
<u>EP 2001-937179</u>	A3	20010412
<u>EP 2006-15131</u>	A3	20010412
<u>EP 2006-76852</u>	A3	20010412
<u>EP 2008-75327</u>	A3	20010412
<u>EP 2008-75909</u>	A3	20010412
<u>US 2001-832501</u>	B1	20010412
<u>US 2001-833041</u>	A3	20010412
<u>US 2001-833111</u>	A3	20010412
<u>US 2001-833117</u>	B1	20010412
<u>US 2001-833118</u>	A3	20010412
<u>WO 2001-US12013</u>	W	20010412
<u>US 2004-932104</u>	B1	20040902
<u>US 2004-933523</u>	A3	20040903
<u>US 2004-967457</u>	B1	20041019
<u>US 2005-78663</u>	A3	20050314
<u>US 2005-78914</u>	A3	20050314
<u>US 2007-927492</u>	B3	20071029

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses fusion proteins of albumin with various therapeutic proteins. Therapeutic proteins may be stabilized to extend the shelf-life, and/or to retain the therapeutic protein's activity for extended periods of time in soln., in vitro and/or in vivo, by genetically or chem. fusing or conjugating the therapeutic protein to albumin or a fragment or variant of albumin. Use of albumin fusion proteins may also reduce the need to formulate the protein solns. with large excesses of carrier proteins to prevent loss of therapeutic proteins due to factors such as binding to the container. Nucleic acid mols. encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors contg. these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Thus, plasmid vectors are constructed in which DNA encoding the desired therapeutic protein may be inserted for expression of the albumin fusion proteins in yeast (pPPC0005) and mammalian cells (pC4:BSA). Yeast-derived signal sequences from *Saccharomyces cerevisiae* invertase SUC2 gene, or the stanniocalcin or native human serum albumin signal peptides, are used for secretion in yeast or mammalian systems, resp. Thus, the fusion product of human growth hormone with residues 1-387 of human serum albumin retains essentially intact biol. activity after 5 wk of incubation in tissue culture media at 37°, whereas recombinant human growth hormone used as control lost its biol. activity in the first week. Although the potency of the albumin fusion proteins is slightly lower than the unfused counterparts in rapid bioassays, their biol. stability results in much higher biol. activity in the longer term in vitro assay or in vivo assays. Addnl., the present invention encompasses pharmaceutical compns. comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:275313 CAPLUS

DOCUMENT NUMBER: 132:313670
 TITLE: Coated substrates for blood, plasma, or tissue washing and columns equipped with these substrates
 INVENTOR(S): Dunzendorfer, Udo; Will, Gottfried
 PATENT ASSIGNEE(S): Germany
 SOURCE: Ger. Offen., 30 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19845286	A1	20000427	DE 1998-19845286	19981001
EP 1004598	A2	20000531	EP 1999-118541	19990918
EP 1004598	A3	20000607		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PL, RO			<u>DE 1998-19845286</u>	A 19981001

PRIORITY APPLN. INFO.: DE 1998-19845286 A 19981001
 AB Columns, filters, cannulas, etc. contg. substrates coated with specific antibodies can be used during plasmapheresis to remove pathogenic cytokines such as tumor necrosis factor (TNF), anti-TNF, fragments of TNF or anti-TNF, or TNF transport proteins from blood, plasma, or tissues. The substrates may addnl. be coated with antibodies to microbial or viral pathogens or mixts. of pathogens as well as to polysaccharide antigens, viral capsids, microbial antigens, reverse transcriptase, endothelin, protein A, etc. Selective removal of these pathogens, antigens, proteins, etc. leaves all normal plasma components unchanged and obviates the need for supplementation of the plasma with these components. Suitable substrates include polymers, polymer-coated metals, cellulose derivs., starch, and Sepharose; these may be derivatized for covalent binding of the pathogens or pathogenic mols. Thus, Escherichia coli pyelonephritis was successfully treated by plasmapheresis coupled with columns loaded with anti-TNF- α for 14 days, 4 h/day, as dtd. by decreases in plasma TNF- α levels and colony counts in urine cultures.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)

-> L11 and L12
 L13 4 L11 AND L12

=> D L13 IBIB ABS 1-4

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2006:103254 CAPLUS
 DOCUMENT NUMBER: 144:164229
 TITLE: Aminoacridine compounds for the inhibition of NF- κ B, and use in the treatment of cancer and other conditions
 INVENTOR(S): Gudkov, Andrei V.; Gurova, Katerina V.
 PATENT ASSIGNEE(S): Cleveland Clinic Foundation, USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012419	A2	20060202	WO 2005-US25884	20050720
WO 2006012419	A3	20070308		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005267117	A1	20060202	AU 2005-267117	20050720
EP 1771203	A2	20070411	EP 2005-791579	20050720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 20080507545	T	20080313	JP 2007-522754	20050720
US 20070270455	A1	20071122	US 2007-624828	20070119
URITY APPLN. INFO.:			US 2004-5896378	P 20040720
			WO 2005-US25884	S 20050720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN [HTML](#) OR [DISPLAY](#) FORMAT

OTHER SOURCE(S): MABPAT 144:164229

AB Aminoacridines are inhibitors of NF- κ B. Inhibiting NF- κ B leads to reactivation of p53 in cancer cells with functionally blocked p53. The compds. of the invention are useful for the treatment of cancer and other conditions.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

1-13 ANSWER 3 OF 4 CAPTION COPYRIGHT 2011 MCS SP STM

Full Citing
Text References

ACCESSION NUMBER: 2005:962083 CAPLUS
DOCUMENT NUMBER: 143:246766
TITLE: Antibodies, agonists and antagonists of interleukin 27 or IL-27 receptor for diagnosis and treatment of immune disease, inflammation and cancer
INVENTOR(S): Kastelein, Robert A.; McClanahan, Terrill K.; Pflanz, Stefan
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PARENT/END DOCUMENTATION

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079848	A2	20050901	<u>WO 2005-US4902</u>	20050215
WO 2005079848	A3	20051215		
WO 2005079848	A9	20061207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, UD, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

<u>AU 2005215771</u>	A1	20050901	<u>AU 2005-215771</u>	20050215
<u>CA 2555421</u>	A1	20050901	<u>CA 2005-2555421</u>	20050215
<u>US 20050214296</u>	A1	20050929	<u>US 2005-58934</u>	20050215
<u>CN 1921886</u>	A	20070228	<u>CN 2005-80005143</u>	20050215
<u>EP 1755641</u>	A2	20070228	<u>EP 2005-713651</u>	20050215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
<u>BR 200507776</u>	A	20070710	<u>BR 2005-7776</u>	20050215
<u>JP 2007523169</u>	T	20070816	<u>JP 2006-554178</u>	20050215
<u>ZA 200606833</u>	A	20080528	<u>ZA 2006-6833</u>	20060816
<u>MX 200609438</u>	A	20061120	<u>MX 2006-9438</u>	20060817
<u>NO 200604192</u>	A	20061116	<u>NO 2006-4192</u>	20060915
PRIORITY APPLN. INFO.:			<u>US 2004-545762P</u>	P 20040217
			<u>WO 2005-US1902</u>	W 20050215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, are provided. Methods of administering agonists or antagonists of IL-27 and IL-27 receptor, p28, EBI3, WSX/TCCR, and WSX1/TCCR-gp130 complexes are also provided. Agonists or antagonists include antibodies, monoclonal antibodies, polyclonal antibodies, humanized antibodies, antibody fragments, peptide mimetics, or a detectable label.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text References	
ACCESSION NUMBER:	2005:15787 CAPLUS
DOCUMENT NUMBER:	142:92172
TITLE:	Cytokine-expressing cellular vaccine combinations for treatment of cancer
INVENTOR(S):	Jooss, Karin; Creson, Jennifer; Li, Betty; Prell, Rodney; Aung, Sandra; Moskalenko, Marina Boris; Du, Thomas
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 404,662.
DOCUMENT TYPE:	CODEN: USXXCO
LANGUAGE:	Patent
FAMILY ACC. NUM. COUNT:	English
PATENT INFORMATION:	2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 2005002916</u>	A1	20050106	<u>US 2004-807449</u>	20040324
<u>US 20040197312</u>	A1	20041007	<u>US 2003-404662</u>	20030402

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The disclosed invention provides improved methods and compns. for treating cancer in a mammal (preferably human) based on the administration of the combination of a cytokine-expressing cellular vaccine and at least one addnl. cancer therapeutic agent or treatment to a patient with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular vaccine or cancer therapeutic agent or treatment as a monotherapy. The examples present the use of cytokine-expressing cellular vaccine (GVAX) in combination with different cancer therapeutic agents in a murine melanoma model (B16F10), renal cell carcinoma (renca), colon carcinoma (CT26), breast carcinoma (4T1), lung cancer (LLC), and fibrosarcoma (3T3).

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2003:133790 CAPLUS
 DOCUMENT NUMBER: 1381:168828
 TITLE: Cytokine receptor-activating agent and co-stimulatory molecule-activating agent for prevention or treatment of cancer, inflammatory disorders or infectious diseases
 INVENTOR(S): Chen, Shu-Hsia; Pan, Ping-Yan; Woo, Savio L. C.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 735,296.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 20030035790</u>	A1	20030220	<u>US 2002-165643</u>	20020607
<u>PRIORITY APPLN. INFO.:</u>			<u>US 1999-115992P</u>	P 19990115
			<u>US 2000-735296</u>	A2 20000114

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to compns. comprising compds. which augment activated immune cells, such as T-cells, dendritic cells and natural killer ("NK") cells, and methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising the administration of said compns. to said subject. In particular, the present invention relates to methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising administering to said subject one or more compds. that activate one or more cytokine receptors and one or more compds. that activate one or more co-stimulatory mols. expressed by activated immune cells. The present invention also relates to compns. and kits comprising a compd. that activates one or more cytokine receptors and a compd. that activates one or more co-stimulatory mols. expressed by activated immune cells.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

> L11 not L13

L14 14 L11 NOT L13

-> L12 not L13

L15 22 L12 NOT L13

-> D L14 IBIB ABS 1-14

L14 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2007:590829 CAPLUS
 DOCUMENT NUMBER: 147:29577
 TITLE: Monoclonal antibody to human CD134 (OX40) for diagnosis and treatment of inflammation and autoimmune disease
 INVENTOR(S): Kato, Shinichiro; Soloff Nugent, Rachel; Yoshida, Hitoshi; Croft, Michael
 PATENT ASSIGNEE(S): Kirin Beer Kabushiki Kaisha, Japan; La Jolla Institute for Allergy and Immunology
 SOURCE: PCT Int. Appl., 110pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2007062245</u>	A2	20070531	<u>WO 2006-US45522</u>	20061127
<u>WO 2007062245</u>	A3	20071206		
W: AT, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OR				
<u>AU 2006318329</u>	A1	20070531	<u>AU 2006-318329</u>	20061127
<u>CA 2631015</u>	A1	20070531	<u>CA 2006-2631015</u>	20061127
<u>EP 1951760</u>	A2	20080806	<u>EP 2006-838473</u>	20061127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
<u>JP 2009518005</u>	T	20090507	<u>JP 2008-542473</u>	20061127
<u>KR 2008080503</u>	A	20080904	<u>KR 2008-7012371</u>	20080523
<u>CN 101331150</u>	A	20081224	<u>CN 2006-80044085</u>	20080526
<u>US 20100196359</u>	A1	20100805	<u>US 2009-87436</u>	20091231
<u>PRIORITY APPN. INFO.:</u>			<u>US 2005-739659P</u>	P 20051125
			<u>WO 2006-US45522</u>	W 20061127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods

including treatment, screening and detection methods.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L14 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2006:499339 CAPLUS
DOCUMENT NUMBER: 145:312828
TITLE: Costimulation and autoimmune diabetes in BB rats
AUTHOR(S): Beaudette-Zlatanova, B. C.; Whalen, B.; Zipris, D.;
Yagita, H.; Rozing, J.; Groen, H.; Benjamin, C. D.;
Hunig, T.; Drexhage, H. A.; Ansari, M. J.; Leif, J.;
Mordes, J. P.; Greiner, D. L.; Sayegh, M. H.; Rossini,
A. A.
CORPORATE SOURCE: Department of Medicine, The University of
Massachusetts Medical School, Worcester, MA, USA
SOURCE: American Journal of Transplantation (2006), 6(5, Pt.
1), 894-902
CODEN: AJTMBR; ISSN: 1600-6135
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Costimulatory signals regulate T-cell activation. To investigate the role of costimulation in autoimmunity and transplantation, we studied the BB rat model of type 1 diabetes. Diabetes-prone BB (BBDP) rats spontaneously develop disease when 55-120 days of age. We observed that two anti-CD28 monoclonal antibodies (mAb) with different functional activities completely prevented diabetes in BBDP rats. Anti-CD154 mAb delayed diabetes, whereas treatment with CTLA4-Ig or anti-CD80 mAb accelerated disease. Anti-CD86 or anti-CD134L mAbs had no effect. Diabetes resistant BB (BBDR) rats are disease-free, but >95% of them develop diabetes after treatment with polyinosinic-polycytidylic acid and an mAb that depletes Treg cells. In the induced BBDR model, anti-CD154 mAb delayed onset of diabetes, whereas CTLA4-Ig, anti-CD134L or either of the anti-CD28 mAbs had little or no effect. In contrast, blockade of the CD134-CD134L pathway was highly effective for preventing autoimmune recurrence against syngeneic islet grafts in diabetic BBDR hosts. Blockade of the CD40-CD154 pathway was also effective, but less so. These data suggest that the effectiveness of costimulation blockade in the treatment of type 1 diabetes is dependent on both the costimulatory pathway targeted and the mechanism of induction, stage, intensity and duration of the pathogenic process.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2006:269330 CAPLUS
DOCUMENT NUMBER: 144:348888
TITLE: Anti-OX40L antibodies for prophylaxis, diagnosis and
therapy of inflammatory diseases
INVENTOR(S): Endl, Josef; Eugui, Elsie; Fuentes, Maria; Graus, Yvo;
Labrijn, Aran; Lanzendorfer, Martin; Parren, Paul;
Rebers, Frank; Schumacher, Ralf; Seeber, Stefan; Van
de Winkel, Jan; Van Vugt, Martine
PATENT ASSIGNEE(S): F.Hoffmann-La Roche AG, Switz.

SOURCE: PCT Int. Appl., 137 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2006029879</u>	A2	20060323	<u>WO 2005-EP9968</u>	20050916
<u>WO 2006029879</u>	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
<u>TW 309240</u>	B	20090501	<u>TW 2005-131726</u>	20050914
<u>AR 51925</u>	A1	20070221	<u>AR 2005-103851</u>	20050915
<u>AU 2005284310</u>	A1	20060323	<u>AU 2005-284310</u>	20050916
<u>CA 2580140</u>	A1	20060323	<u>CA 2005-2580140</u>	20050916
<u>EP 1791869</u>	A2	20070606	<u>EP 2005-791827</u>	20050916
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
<u>CN 101023102</u>	A	20070822	<u>CN 2005-80031358</u>	20050916
<u>JP 2008512995</u>	T	20080501	<u>JP 2007-531688</u>	20050916
<u>JP 4594986</u>	B2	20101208		
<u>BR 2005015554</u>	A	20080729	<u>BR 2005-15554</u>	20050916
<u>SG 147444</u>	A1	20081128	<u>SG 2008-7730</u>	20050916
<u>US 7501496</u>	B1	20090310	<u>US 2005-229162</u>	20050916
<u>NZ 553333</u>	A	20090925	<u>NZ 2005-553333</u>	20050916
<u>CN 101684157</u>	A	20100331	<u>CN 2009-10142533</u>	20050916
<u>NZ 579022</u>	A	20100430	<u>NZ 2005-579022</u>	20050916
<u>RU 2395523</u>	C2	20100727	<u>RU 2007-114328</u>	20050916
<u>EP 2218782</u>	A2	20100818	<u>EP 2010-155663</u>	20050916
<u>EP 2218782</u>	A3	20110126		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
<u>ZA 2007001952</u>	A	20081029	<u>ZA 2007-1952</u>	20070306
<u>MX 2007002905</u>	A	20070508	<u>MX 2007-2905</u>	20070309
<u>KR 2007050972</u>	A	20070516	<u>KR 2007-7006191</u>	20070316
<u>KR 901090</u>	B1	20090608		
<u>IN 2007CN01147</u>	A	20070817	<u>IN 2007-CN1147</u>	20070319
<u>IN 239940</u>	A1	20100423		
<u>KR 2008059471</u>	A	20080627	<u>KR 2008-7012656</u>	20080527
<u>KR 895597</u>	B1	20090506		
<u>US 20100166740</u>	A1	20100701	<u>US 2008-315863</u>	20081205
<u>US 7868141</u>	B2	20110111		
<u>IN 2009CN04675</u>	A	20091030	<u>IN 2009-CN4675</u>	20090807
<u>JP 2010280673</u>	A	20101216	<u>JP 2010-158015</u>	20100712
<u>US 20110070239</u>	A1	20110324	<u>US 2010-958278</u>	20101201
<u>PRIORITY APPLN. INFO.:</u>			<u>EP 2004-22158</u>	<u>A 20040917</u>
			<u>EP 2004-30546</u>	<u>A 20041223</u>
			<u>CN 2005-80031358</u>	<u>A3 20050916</u>

EP 2005-791827	A3 20050916
JP 2007-531688	A3 20050916
US 2005-229162	A3 20050916
WO 2005-EP9968	W 20050916
KR 2007-7006191	A3 20070316
IN 2007-CN1147	A3 20070319
US 2008-315863	A3 20081205

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2006:164938 CAPLUS
 DOCUMENT NUMBER: 1451186153
 TITLE: Roles of OX40 in the pathogenesis and the control of diseases
 AUTHOR(S): Hori, Toshiyuki
 CORPORATE SOURCE: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
 SOURCE: International Journal of Hematology (2006), 83(1), 17-22
 CODEN: IJHEEY; ISSN: 0925-5710
 PUBLISHER: Carden Jennings Publishing
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. OX40 belongs to the tumor necrosis factor receptor superfamily, and its expression is restricted to activated T-cells. Ligation of OX40 during T-cell-dendritic cell interaction is crucial for clonal expansion of antigen-specific T-cells and generation of T-cell memory. The ligand of OX40 (OX40L) is expressed not only on dendritic cells but also on other cell types, such as B-cells, vascular endothelial cells, natural killer cells, and mast cells. The pathophysiol. relevance of this broad distribution needs further investigation. In particular, OX40L on vascular endothelial cells may play a role in inflammatory vasculitis as well as in atherosclerotic change. Recent studies with animal models have indicated the crit. involvement of OX40 in the pathogenesis of a variety of immunol. abnormalities of inflammatory, autoimmune, infectious, allergic, and allotransplantationrelated diseases. Blockade of OX40-OX40L interaction has been shown to prevent, cure, or ameliorate these diseases. In contrast, activation of OX40 is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. These findings clearly suggest that the OX40/OX40L system is one of the most promising targets of immune intervention for treatment of these diseases.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2005:729611 CAPLUS
 DOCUMENT NUMBER: 143:206465
 TITLE: Therapeutic and carrier molecules
 INVENTOR(S): Ferrante, Antonio; Rathjen, Deborah Ann
 PATENT ASSIGNEE(S): Peplin Biolipids Pty Ltd, Australia
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2005073164</u>	A1	20050811	<u>WO 2005-AU98</u>	20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>AU 2005209331</u>	A1	20050811	<u>AU 2005-209331</u>	20050128
<u>CA 2554735</u>	A1	20050811	<u>CA 2005-2554735</u>	20050128
<u>EP 1718602</u>	A1	20061108	<u>EP 2005-700130</u>	20050128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
<u>CN 1934072</u>	A	20070321	<u>CN 2005-80008891</u>	20050128
<u>BR 2005007236</u>	A	20070626	<u>BR 2005-7236</u>	20050128
<u>JP 2007522118</u>	T	20070809	<u>JP 2006-549788</u>	20050128
<u>US 20090215895</u>	A1	20090827	<u>US 2009-588094</u>	20090507
<u>PRIORITY APPLN. INFO.:</u>			<u>US 2004-540604P</u>	P 20040130
			<u>WO 2005-AU98</u>	W 20050128

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:206465

AB The present invention relates generally to compds. comprising a hydrocarbon chain portion and more particular to compds. comprising chem. derivatizations of the hydrocarbon chain which are useful therapeutic and prophylactic mols. The present invention further provides compds. where the hydrocarbon chain portion is a carrier mol. for functional groups, moieties or agents. The present invention can include naturally including polyunsatd. fatty acids as well as synthetic, modified or derivatized polyunsatd. fatty acids. Furthermore, these polyunsatd. fatty acids can be conjugated to amino acids, peptides or proteins. The compds. of the present invention are particularly useful in the treatment and prophylaxis of a range of conditions including cancers, protein kinase c(PKC)- or NFkB-related- or -assoccd. conditions, cardiovascular conditions, pain, inflammatory conditions, vascular or immunol. conditions such as diabetes, neurol. conditions and infection by a range of viruses or prokaryotic or eukaryotic organisms. The present invention further provides pharmaceutical compns. and methods of medical treatment.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2004:589563 CAPLUS
 DOCUMENT NUMBER: 141:134075
 TITLE: Treatment of inflammation with combinations of inhibitors of interleukin 1 and of inhibitors of lymphocyte activation
 INVENTOR(S): Khare, Sanjay Deep
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 203 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2004060911</u>	A2	20040722	<u>WO 2003-US41378</u>	20031224
<u>WO 2004060911</u>	A3	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UA, UC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>CA 2511823</u>	A1	20040722	<u>CA 2003-2511823</u>	20031224
<u>AU 2003299971</u>	A1	20040729	<u>AU 2003-299971</u>	20031224
<u>EP 1578782</u>	A2	20050928	<u>EP 2003-800236</u>	20031224
<u>EP 1578782</u>	A3	20051026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
<u>JP 2006517191</u>	T	20060720	<u>JP 2004-565743</u>	20031224
<u>US 20040208874</u>	A1	20041021	<u>US 2003-748112</u>	20031229
<u>MX 200507019</u>	A	20050818	<u>MX 2005-7019</u>	20050627
<u>US 20080279862</u>	A1	20081113	<u>US 2008-143693</u>	20080620
<u>PRIORITY APPLN. INFO.:</u>			<u>US 2002-437405P</u>	P 20021230
			<u>WO 2003-US41378</u>	W 20031224
			<u>US 2003-748112</u>	A1 20031229

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods for treating inflammation, esp. by preventing lymphocyte activation using combinations of effectors are described. These may include combinations of IL-1 inhibitors and an inhibitor of B cell or T cell activation. The use of the prior art KIN2 fusion protein of interleukin 1 receptor antagonist and Ig Fc to treat inflammation in a collagen-induced arthritis model is demonstrated. The KIN2 fusion protein lessened inflammation when used alone. A fusion protein of CTLA-4 antigen and Ig Fc was ineffective as an inflammation inhibitor when used alone. When the two fusion proteins were used in combination, the effects on the inflammation were longer-lasting than those of KIN2 alone. Similarly, a combination of the CTLA-4 fusion protein and PEGylated tumor necrosis factor receptor 1 was more effective than the receptor alone. Use of viral vectors expressing genes for these

proteins in long-term therapy is also demonstrated.
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPIUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 14 CAPIUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2003:836393 CAPIUS
 DOCUMENT NUMBER: 139:336932
 TITLE: Human tumor necrosis factor- $\gamma\beta$, receptor DR3 and TR6, antagonists and antibodies for diagnosis, prognosis and treatment of inflammatory bowel diseases
 INVENTOR(S): Yu, Guo-liang; Ni, Jian; Rosen, Craig A.; Zhang, Jun; Wei, Ping
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 173 pp., Cont.-in-part of U.S. Ser. No. 226,294.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 20030198640</u>	A1	20031023	<u>US 2002-310793</u>	20021206
<u>WO 9614328</u>	A1	19960517	<u>WO 1994-US12880</u>	19941107
W: AU, CA, CN, RW: AT, BE, CH,	JP, KR, NZ, US DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
<u>JP 2002223781</u>	A	20020813	<u>JP 2001-337585</u>	19941107
<u>US 20030027284</u>	A1	20030206	<u>US 1998-131237</u>	19980807
<u>US 6599719</u>	B2	20030729		
<u>US 20020090683</u>	A1	20020711	<u>US 1999-246129</u>	19990208
<u>US 6824767</u>	B2	20041130		
<u>US 20020150534</u>	A1	20020107	<u>US 2001-899059</u>	20010706
<u>US 7597886</u>	B2	20091006		
<u>US 20030129189</u>	A1	20030710	<u>US 2002-226294</u> <u>WO 1994-US12880</u>	20020823

PRIORITY APPLN. INFO.:

<u>US 1995-461246</u>	B2	19950605
<u>US 1998-5020</u>	B2	19980109
<u>US 1998-74047P</u>	P	19980209
<u>US 1998-131237</u>	A2	19980807
<u>US 1999-246129</u>	A2	19990208
<u>US 1999-131963P</u>	P	19990430
<u>US 1999-132227P</u>	P	19990503
<u>US 1999-134067P</u>	P	19990513
<u>US 2000-180908P</u>	P	20000208
<u>US 2000-559290</u>	B2	20000427
<u>US 2000-216879P</u>	P	20000707
<u>US 2001-278449P</u>	P	20010326
<u>US 2001-899059</u>	A2	20010706
<u>US 2001-314381P</u>	P	20010824
<u>US 2001-336695P</u>	P	20011207
<u>US 2002-226294</u>	A2	20020823
<u>JP 1996-515265</u>	A3	19941107
<u>WO 2000-US11689</u>	A2	20000428

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses methods for detection, diagnosis,

prevention, treatment, and/or amelioration of inflammatory bowel diseases and disorders using TNF- $\gamma\beta$ and its receptors DR3 and TR6. In particular the invention encompasses methods of using TNF- $\gamma\beta$, DR3 and TR6 polypeptides, as well as antibodies, and antagonists thereto, in the diagnosis, prognosis and treatment of ulcerative colitis and/or Crohn's disease. Methods of screening for antagonists of the TNF- $\gamma\beta$ polypeptide, together with therapeutic uses of such antagonists are also disclosed.

L14 ANSWER 8 OF 14 CAPIUS COPYRIGHT 2011 ACS on STN

Full Citing
Text References

ACCESSION NUMBER: 2003:390790 CAPIUS
 DOCUMENT NUMBER: 138:400393
 TITLE: T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions
 INVENTOR(S): Weinberg, Andrew D.; Vandenbergk, Arthur A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,759,546.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 6566082</u>	B1	20030520	<u>US 1995-469633</u>	19950606
<u>US 5759546</u>	A	19980602	<u>US 1994-192480</u>	19940204
<u>WO 9521251</u>	A1	19950810	<u>WO 1995-GB2371</u>	19950206
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>AU 9891341</u>	A	19990114	<u>AU 1998-91341</u>	19981104
<u>AU 9891342</u>	A	19990121	<u>AU 1998-91342</u>	19981104
<u>AU 781082</u>	B2	20050505	<u>AU 2001-19731</u>	20010213
<u>AU 782568</u>	B2	20050811	<u>AU 2001-79325</u>	20011010
<u>JP 2007045832</u>	A	20070222	<u>JP 2006-248393</u>	20060913
<u>PRIORITY APPN. INFO.:</u>			<u>US 1994-192480</u>	A2 19940204
			<u>WO 1995-GB2371</u>	A 19950206
			<u>AU 1995-15835</u>	A3 19950206
			<u>JP 1995-520474</u>	A3 19950206
			<u>AU 1998-91341</u>	A3 19981104
			<u>AU 1998-91342</u>	A3 19981104

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The OX-40 antigen is characterized and claimed together with variants and derivs. thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells (without affecting the non-activated T cells) in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic mol. (such as ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including multiple sclerosis, rheumatoid arthritis, sarcoidosis, and autoimmune uveitis as well as inflammatory bowel disease and graft-vs.-host disease. This type of therapy is also

beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2002:793447 CAPLUS
 DOCUMENT NUMBER: 137:304813
 TITLE: Modulators of hedgehog signaling pathway for treatment of T-cell-mediated diseases
 INVENTOR(S): Lamb, Jonathan Robert; Hoyne, Gerard Francis; Dallman, Margaret Jane; Champion, Brian Robert
 PATENT ASSIGNEE(S): Lorantis Limited, UK
 SOURCE: PCT Int. Appl., 154 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080952	A2	20021017	WO 2002-GB1666	20020409
WO 2002080952	A3	20040108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002247847	A1	20021021	AU 2002-247847	20020409
EP 1401469	A2	20040331	EP 2002-716928	20020409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534743	T	20041118	JP 2002-578991	20020409
US 20040126359	A1	20040701	US 2003-682230	20031009
PRIORITY APPLN. INFO.:			GB 2001-8872	A 20010409
			GB 2001-8873	A 20010409
			WO 2002-GB1666	W 20020409

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Use of a modulator of a Hedgehog signaling pathway, or a modulator of a pathway which is a target of the Hedgehog signaling pathway in the prepn. of a medicament for treatment of a disease or disorder assocd. with a T-cell mediated disease or disorder.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2001:884232 CAPLUS
DOCUMENT NUMBER:	136:149820
TITLE:	Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
AUTHOR(S):	Kjaergaard, Jorgen; Peng, Liaomin; Cohen, Peter A.; Drazba, Judith A.; Weinberg, Andrew D.; Shu, Suyu
CORPORATE SOURCE:	Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
SOURCE:	Journal of Immunology (2001), 167(11), 6669-6677
PUBLISHER:	CODEN: JOIM3; ISSN: 0022-1767
DOCUMENT TYPE:	American Association of Immunologists
LANGUAGE:	Journal English
AB	Therapeutic efficacy of adoptive immunotherapy of malignancies is proportional to the no. of effector T cells transferred. Traditionally, exogenous IL-2 treatment has been used to promote the survival and function of transferred cells. Recently, we described the therapeutic effects of <i>in vivo</i> ligation of the costimulatory receptor, OX-40R, on activated T cells during early tumor growth. In this study, we examined the effects of IL-2 and OX-40R mAb on adoptive immunotherapy of advanced tumors. For treatment of 10-day 3-methylcholanthrene 205 pulmonary metastases, systemic transfer of 50 × 10 ⁶ activated tumor-draining lymph node T cells resulted in >99% redn. of metastatic nodules. With either IL-2 or OX-40R mAb conjunctinal treatment, only 20 × 10 ⁶ cells were required. Advanced 10-day 3-methylcholanthrene 205 intracranial tumors could be cured by the transfer of 15 × 10 ⁶ L-selectinlow T cells derived from draining lymph nodes. In this situation, IL-2 administration inhibited therapeutic effects of the transferred cells. By contrast, 5 × 10 ⁶ T cells were sufficient to cure all mice if OX-40R mAb was administrated. Studies on trafficking of systemically transferred T cells revealed that IL-2, but not OX-40R mAb, impeded tumor infiltration by T cells. Tumor regression required participation of both CD4 and CD8 T cells. Because only CD4 T cells expressed OX-40R at cell transfer, direct CD4 T cell activation is possible. Alternatively, OX-40R might be up-regulated on transferred T cells at the tumor site, rendering them reactive to the mAb. Our study suggests OX-40R mAb to be a reagent of choice to augment T cell adoptive immunotherapy in clin. trials.
OS.CITING REF COUNT:	44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS RECORD (44 CITINGS)
REFERENCE COUNT:	53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2001:777015 CAPLUS
DOCUMENT NUMBER:	135:329667
TITLE:	Adult T-cell leukemia (ATL)
AUTHOR(S):	Uchiyama, Takashi
CORPORATE SOURCE:	Grad. Sch. Med., Kyoto Univ., Japan
SOURCE:	Nippon Naika Gakkai Zasshi (2001), 90(9), 1865-1871
PUBLISHER:	CODEN: NNGAAS; ISSN: 0021-5384
DOCUMENT TYPE:	Nippon Naika Gakkai
LANGUAGE:	Journal; General Review Japanese

AB A review with refs., on recent progress in studies on the mechanism and treatment of HTLV-I (human T cell leukemia virus type I)-caused adult T-cell leukemia, discussing clin. features, *in vivo* proliferation mechanism of ATL cells, roles of OX40/gp34 (OX40 ligand) in *in vivo* proliferation of ATL cells, and therapeutic approach to ATL.

L14 ANSWER 12 OF 14 CAPIPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2001:265459 CAPIPLUS
 DOCUMENT NUMBER: 134:290751
 TITLE: Recombinant single-chain receptor antagonist proteins and their use in treatment of inflammatory disorders
 INVENTOR(S): Halkier, Torben; Schambye, Hans Thalsgard; Okkels, Jens Sigurd; Andersen, Kim Vilbour; Nissen, Torben Lauesgaard; Soni, Bobby; Jeppesen, Claus Bekker; Van Den Hazel, Bart
 PATENT ASSIGNEE(S): Maxygen Aps, Den.
 SOURCE: PCT Int. Appl., 123 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2001025277</u>	A1	20010412	<u>WO 2000-DK563</u>	20001006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>EP 1226173</u>	A1	20020731	<u>EP 2000-965860</u>	20001006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
<u>US 20040014948</u>	A1	20040122	<u>US 2003-444691</u>	20030523
PRIORITY APPN. INFO.:			<u>DK 1999-1438</u>	A 19991007
			<u>DK 1999-1855</u>	A 19991223
			<u>DK 2000-1119</u>	A 20000720
			<u>US 1999-160820P</u>	P 19991021
			<u>US 2000-174655P</u>	P 20000106
			<u>US 2000-225723P</u>	P 20000816
			<u>US 2000-684720</u>	B1 20001006
			<u>WO 2000-DK563</u>	W 20001006

AB The invention relates to a single-chain oligomeric protein antagonist which binds to an extracellular ligand-binding domain of a cellular receptor of a type requiring binding of an oligomeric ligand to two or more receptor subunits to be activated, the protein comprising at least two, typically structurally homologous, receptor-binding sites of which at least one is capable of binding to a ligand-binding domain of the cellular receptor and at least one is incapable of effectively binding to a ligand-binding domain of the cellular receptor, whereby the single-chain oligomeric protein is capable of binding to the receptor, but incapable of activating the receptor; as well as to nucleotide sequences encoding such single-chain oligomeric proteins, expression vectors comprising such a

nucleotide sequence, recombinant host cells comprising such a nucleotide sequence or expression vector, methods for producing the nucleotide sequences and proteins, pharmaceutical compns, comprising the single-chain oligomeric protein, and use of the single-chain oligomeric protein for the prodn. of medicaments and in therapy. A preferred single-chain antagonist according to the invention is a TNF- α antagonist. Thus, a single-chain TNF- α protein comprising of 3 human TNF- α chains connected by linker peptides was produced with *Saccharomyces cerevisiae* and shown to be an agonist of the TNF- α receptor. The same TNF- α trimer contg. Y87R mutations in the first and third copies of TNF- α was also prep'd. This was shown to be a partial TNF- α agonist and a competitive antagonist of the TNF- α receptor.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citng
 Text References

ACCESSION NUMBER: 1999;549381 CAPLUS
DOCUMENT NUMBER: 131;156919
TITLE: Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
INVENTOR(S): Weinberg, Andrew D.
PATENT ASSIGNEE(S): Sisters of Providence In Oregon, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9942585</u>	A1	19990826	<u>WO 1999-US3908</u>	19990223
W: AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>CA 2321161</u>	A1	19990826	<u>CA 1999-2321161</u>	19990223
<u>AU 9928739</u>	A	19990906	<u>AU 1999-28739</u>	19990223
<u>EP 1060247</u>	A1	20001220	<u>EP 1999-909562</u>	19990223
<u>EP 1060247</u>	B1	20080910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
<u>JP 2002504334</u>	T	20020212	<u>JP 2000-532525</u>	19990223
<u>AP 1261</u>	A	20040319	<u>AP 2000-1903</u>	19990223
<u>AT 408011</u>	T	20080915	<u>AT 1999-909562</u>	19990223
<u>EP 1997893</u>	A1	20081203	<u>EP 2008-15510</u>	19990223
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
<u>PT 1060247</u>	E	20081222	<u>PT 1999-909562</u>	19990223
<u>ES 2315008</u>	T3	20090316	<u>ES 1999-909562</u>	19990223
<u>MX 2000008176</u>	A	20020311	<u>MX 2000-8176</u>	20000821

AU 2002302070 AU 2002302070	A1 20030320 B2 20071115	AU 2002-302070	20021120
<u>PRIORITY APPLN. INFO.:</u>			
		US 1998-28716	A 19980224
		AU 1999-28739	A3 19990223
		EP 1999-909562	A3 19990223
		WO 1999-US3908	W 19990223
AB Compns. and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed. The compn. administered to the mammal comprises a purified OX-40 receptor binding agent and a pharmaceutically acceptable carrier, wherein said compn. is administered to the mammal such that the OX-40 receptor binding agent is presented to T-cells of the mammal during or shortly after priming of the T-cells by the antigen. The OX-40 receptor binding agent may comprise an OX-40 ligand (a member of the tumor necrosis factor superfamily) or anti-OX-40 antibodies. Engagement of the OX-40 receptor on CD4+ T-cells esp. during, or shortly after, priming of such cells by antigen, can result in an increased response of the CD4+ T-cells to that antigen, and the elevated response to that antigen is maintained for a period of time substantially longer than in the absence of such an engagement. As a result of such engagement, the resistance of an animal to disease is markedly increased with improved T-cell recognition of antigens presented by infectious agents, such as bacteria and viruses, as well as tumor cells. Such compns. and methods can be used in immunization and cancer treatment. Human OX-40 ligand:Ig fusion protein is an example of a protein applicable to the present invention that can be used in human clin. trials and can stimulate human T cells.			
OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)	
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	
L14 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2011 ACS on STN			
<input checked="" type="checkbox"/> Full <input type="checkbox"/> Citing <input type="checkbox"/> Text <input type="checkbox"/> References			
ACCESSION NUMBER:	1995:916524	CAPLUS	
DOCUMENT NUMBER:	123:312224		
ORIGINAL REFERENCE NO.:	123:55959a,55962a		
TITLE:	OX-40 antigen of T lymphocyte for use in diagnosis and treatment of T cell-mediated conditions		
INVENTOR(S):	Weinberg, Andrew Dale; Vandenberg, Arthur Allen		
PATENT ASSIGNEE(S):	Cantab Pharmaceuticals Research Ltd., UK		
SOURCE:	PCT Int. Appl., 92 pp.		
CODEN:	PIXD2		
DOCUMENT TYPE:	Patent		
LANGUAGE:	English		
FAMILY ACC. NUM. COUNT:	2		
<u>PATENT INFORMATION:</u>			
PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	-----	-----
WO 9521251	A1	19950810	WO 1995-GB237
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US			19950206
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5759546	A	19980602	US 1994-192480
CA 2182685	A1	19950810	CA 1995-2182685
			19940204
			19950206

AU 9515835	A	19950821	AU 1995-15835	19950206
EP 742823	A1	19961120	EP 1995-907738	19950206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	T	19970916	JP 1995-520474	19950206
JP 09509053	B1	20030520	US 1995-469633	19950606
US 6566082	A	19990114	AU 1998-91341	19981104
AU 9891341	A	19990121	AU 1998-91342	19981104
AU 9891342	B2	20050505	AU 2001-19731	20010213
AU 781082	B2	20050811	AU 2001-79325	20010101
AU 782568	A	20070222	JP 2006-248393	20060913
JP 2007045832			US 1994-192480	A 19940204
PRIORITY APPLN. INFO.:			AU 1995-15835	A3 19950206
			JP 1995-520474	A3 19950206
			WO 1995-GB237	W 19950206
			AU 1998-91341	A3 19981104
			AU 1998-91342	A3 19981104

AB T lymphocyte **OX-40 antigen** and binding agent (e.g. antibody) for the **antigen** are provided for diagnosis and **treatment** of T cell-mediated diseases. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a cytotoxic mol. (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including multiple sclerosis, rheumatoid arthritis, sarcoidosis, and autoimmune uveitis as well as inflammatory bowel disease and graft-vs.-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with the transplantation reaction.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

-> D L11 IBIB ABS 1-18

L11 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	20071590829 CAPLUS
DOCUMENT NUMBER:	147:29577
TITLE:	Monoclonal antibody to human CD134 (OX40) for diagnosis and treatment of inflammation and autoimmune disease
INVENTOR(S):	Kato, Shinichiro; Soloff Nugent, Rachel; Yoshida, Hitoshi; Croft, Michael
PATENT ASSIGNEE(S):	Kirin Beer Kabushiki Kaisha, Japan; La Jolla Institute for Allergy and Immunology
SOURCE:	PCT Int. Appl., 110pp.
DOCUMENT TYPE:	CODEN: PIXXD2
LANGUAGE:	Patent
FAMILY ACC. NUM. COUNT:	English
PATENT INFORMATION:	1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007D62245	A2	20070531	WO 2006-US45522	20061127
WO 2007D62245	A3	20071206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,

KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
<u>AU 2006318329</u>	A1 20070531	<u>AU 2006-318329</u>	20061127
<u>CA 2631015</u>	A1 20070531	<u>CA 2006-2631015</u>	20061127
<u>EP 1951760</u>	A2 20080806	<u>EP 2006-838473</u>	20061127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
<u>JP 2009518005</u>	T 20090507	<u>JP 2008-542473</u>	20061127
<u>KR 2008080503</u>	A 20080904	<u>KR 2008-7012371</u>	20080523
<u>CN 101331150</u>	A 20081224	<u>CN 2006-80044085</u>	20080526
<u>US 20100196359</u>	A1 20100805	<u>US 2009-87436</u>	20091231
<u>PRIORITY APPLN. INFO.:</u>			
<u>US 2005-7396599</u> P 20051125			
<u>WO 2006-US45522</u> W 20061127			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L11 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2006:499339 CAPLUS
DOCUMENT NUMBER:	145:312828
TITLE:	Costimulation and autoimmune diabetes in BB rats
AUTHOR(S):	Beaudette-Zlatanova, B. C.; Whalen, B.; Zipris, D.; Yagita, H.; Rozing, J.; Groen, H.; Benjamin, C. D.; Hunig, T.; Drexhage, H. A.; Ansari, M. J.; Leif, J.; Mordes, J. P.; Greiner, D. L.; Sayegh, M. H.; Rossini, A. A.
CORPORATE SOURCE:	Department of Medicine, The University of Massachusetts Medical School, Worcester, MA, USA
SOURCE:	American Journal of Transplantation (2006), 6(5, Pt. 1), 894-902
PUBLISHER:	Blackwell Publishing Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Costimulatory signals regulate T-cell activation. To investigate the role of costimulation in autoimmunity and transplantation, we studied the BB rat model of type 1 diabetes. Diabetes-prone BB (BBDP) rats spontaneously develop disease when 55-120 days of age. We obsev. that two anti-CD28 monoclonal antibodies (mAb) with different functional activities completely prevented diabetes in BBDP rats. Anti-CD154 mAb delayed diabetes, whereas treatment with CTLA4-Ig or anti-CD80 mAb accelerated disease. Anti-CD86 or anti-CD134L mAbs had no effect. Diabetes resistant

BB (BBDR) rats are disease-free, but >95% of them develop diabetes after treatment with polyinosinic-polycytidylic acid and an mAb that depletes Treg cells. In the induced BBDR model, anti-CD154 mAb delayed onset of diabetes, whereas CTLA4-Ig, anti-CD134L or either of the anti-CD28 mAbs had little or no effect. In contrast, blockade of the CD134-CD134L pathway was highly effective for preventing autoimmune recurrence against syngeneic islet grafts in diabetic BBDR hosts. Blockade of the CD40-CD154 pathway was also effective, but less so. These data suggest that the effectiveness of costimulation blockade in the treatment of type 1 diabetes is dependent on both the costimulatory pathway targeted and the mechanism of induction, stage, intensity and duration of the pathogenic process.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2006:269330 CAPLUS
DOCUMENT NUMBER:	144:348888
TITLE:	Anti-OX40L antibodies for prophylaxis, diagnosis and therapy of inflammatory diseases
INVENTOR(S):	Endl, Josef; Eugui, Elsie; Fuentes, Maria; Graus, Yvo; Labrijn, Aran; Lanzendoerfer, Martin; Parren, Paul; Rebers, Frank; Schumacher, Ralf; Seeber, Stefan; Van de Winkel, Jan; Van Vugt, Martine
PATENT ASSIGNEE(S):	F.Hoffmann-La Roche AG, Switz.
SOURCE:	PCT Int. Appl., 137 pp.
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
<u>PATENT INFORMATION:</u>	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2006029879</u>	A2	20060323	<u>WO 2005-EP996B</u>	20050916
<u>WO 2006029879</u>	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
<u>TW 309240</u>	B	20090501	<u>TW 2005-131726</u>	20050914
<u>AR 51925</u>	A1	20070221	<u>AR 2005-103851</u>	20050915
<u>AU 2005284310</u>	A1	20060323	<u>AU 2005-284310</u>	20050916
<u>CA 2580140</u>	A1	20060323	<u>CA 2005-2580140</u>	20050916
<u>EP 1791869</u>	A2	20070606	<u>EP 2005-791827</u>	20050916
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
<u>CN 101023102</u>	A	20070822	<u>CN 2005-80031358</u>	20050916

<u>JP 2008512995</u>	T	20080501	<u>JP 2007-531688</u>	20050916
<u>JP 4594986</u>	B2	20101208	<u>BR 2005-15554</u>	20050916
<u>BR 2005015554</u>	A	20080729	<u>SG 2008-7730</u>	20050916
<u>SG 147444</u>	A1	20081128	<u>US 2005-229162</u>	20050916
<u>US 7501496</u>	B1	20090310	<u>NZ 2005-553333</u>	20050916
<u>NZ 553333</u>	A	20090925	<u>CN 2009-10142533</u>	20050916
<u>CN 101684157</u>	A	20100331	<u>EP 2010-155663</u>	20050916
<u>NZ 579022</u>	A	20100430	<u>NZ 2005-579022</u>	20050916
<u>RU 2395523</u>	C2	20100727	<u>RU 2007-114328</u>	20050916
<u>EP 2218782</u>	A2	20100818	<u>EP 2010-155663</u>	20050916
<u>EP 2218782</u>	A3	20110126		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
<u>ZA 2007001952</u>	A	20081029	<u>ZA 2007-1952</u>	20070306
<u>MX 2007002905</u>	A	20070508	<u>MX 2007-2905</u>	20070309
<u>KR 2007050972</u>	A	20070516	<u>KR 2007-7006191</u>	20070316
<u>KR 901090</u>	B1	20090608		
<u>IN 2007CN01147</u>	A	20070817	<u>IN 2007-CN1147</u>	20070319
<u>IN 239940</u>	A1	20100423		
<u>KR 2008059471</u>	A	20080627	<u>KR 2008-7012656</u>	20080527
<u>KR 895597</u>	B1	20090506		
<u>US 20100166740</u>	A1	20100701	<u>US 2008-315863</u>	20081205
<u>US 7868141</u>	B2	20110111		
<u>IN 2009CN04675</u>	A	20091030	<u>IN 2009-CN4675</u>	20090807
<u>JP 2010280673</u>	A	20101216	<u>JP 2010-158015</u>	20100712
<u>US 20110070239</u>	A1	20110324	<u>US 2010-958278</u>	20101201
PRIORITY APPLN. INFO.:			<u>EP 2004-22158</u>	A 20040917
			<u>EP 2004-30546</u>	A 20041223
			<u>CN 2005-80031358</u>	A3 20050916
			<u>EP 2005-791827</u>	A3 20050916
			<u>JP 2007-531688</u>	A3 20050916
			<u>US 2005-229162</u>	A3 20050916
			<u>WO 2005-EP9968</u>	W 20050916
			<u>KR 2007-7006191</u>	A3 20070316
			<u>IN 2007-CN1147</u>	A3 20070319
			<u>US 2008-315863</u>	A3 20081205

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:

2006:164938 CAPLUS

DOCUMENT NUMBER:

1451:186153

TITLE:

Roles of OX40 in the pathogenesis and the control of diseases

AUTHOR(S) :

Hori, Toshiyuki

CORPORATE SOURCE:

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

SOURCE:

International Journal of Hematology (2006), 83(1),

17-22

CODEN: IJHEEY; ISSN: 0925-5710

PUBLISHER: Carden Jennings Publishing
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review. OX40 belongs to the tumor necrosis factor receptor superfamily, and its expression is restricted to activated T-cells. Ligation of OX40 during T-cell-dendritic cell interaction is crucial for clonal expansion of antigen-specific T-cells and generation of T-cell memory. The ligand of OX40 (OX40L) is expressed not only on dendritic cells but also on other cell types, such as B-cells, vascular endothelial cells, natural killer cells, and mast cells. The pathophysiol. relevance of this broad distribution needs further investigation. In particular, OX40L on vascular endothelial cells may play a role in inflammatory vasculitis as well as in atherosclerotic change. Recent studies with animal models have indicated the crit. involvement of OX40 in the pathogenesis of a variety of immunol. abnormalities of inflammatory, autoimmune, infectious, allergic, and allotransplantationrelated diseases. Blockade of OX40-OX40L interaction has been shown to prevent, cure, or ameliorate these diseases. In contrast, activation of OX40 is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. These findings clearly suggest that the OX40/OX40L system is one of the most promising targets of immune intervention for treatment of these diseases.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
Text References

ACCESSION NUMBER: 2006103254 CAPLUS
 DOCUMENT NUMBER: 1441164229
 TITLE: Aminoacridine compounds for the inhibition of NF- κ B, and use in the treatment of cancer and other conditions
 INVENTOR(S): Gudkov, Andrei V.; Gurova, Katerina V.
 PATENT ASSIGNEE(S): Cleveland Clinic Foundation, USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012419	A2	20060202	WO 2005-US25884	20050720
WO 2006012419	A3	20070308		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

<u>AU 2005267117</u>	A1	20060202	<u>AU 2005-267117</u>	20050720
<u>EP 1717203</u>	A2	20070411	<u>EP 2005-791579</u>	20050720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
<u>JP 2008507545</u>	T	20080313	<u>JP 2007-522754</u>	20050720
<u>US 20070270455</u>	A1	20071122	<u>US 2007-624828</u>	20070119
PRIORITY APPLN. INFO.:			<u>US 2004-589637P</u>	P 20040720
			<u>WO 2005-US25884</u>	W 20050720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE (S): MARPAT 144:164229

AB Aminoacridines are inhibitors of NF- κ B. Inhibiting NF- κ B leads to reactivation of p53 in cancer cells with functionally blocked p53. The compds. of the invention are useful for the treatment of cancer and other conditions.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L11 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2005:962083 CAPLUS
 DOCUMENT NUMBER: 143:246766
 TITLE: Antibodies, agonists and antagonists of interleukin 27 or IL-27 receptor for diagnosis and treatment of immune disease, inflammation and cancer
 INVENTOR(S): Kastelein, Robert A.; McClanahan, Terrill K.; Pflanz, Stefan
 PATENT ASSIGNEE (S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2005079848</u>	A2	20050901	<u>WO 2005-US4902</u>	20050215
<u>WO 2005079848</u>	A3	20051215		
<u>WO 2005079848</u>	A9	20061207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>AU 2005215771</u>	A1	20050901	<u>AU 2005-215771</u>	20050215
<u>CA 2555421</u>	A1	20050901	<u>CA 2005-2555421</u>	20050215
<u>US 20050214296</u>	A1	20050929	<u>US 2005-58934</u>	20050215
<u>CN 1921886</u>	A	20070228	<u>CN 2005-80005143</u>	20050215
<u>EP 1755641</u>	A2	20070228	<u>EP 2005-713651</u>	20050215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

BR 2005007776	A	20070710	BR 2005-7776	20050215
JP 2007523169	T	20070816	JP 2006-554178	20050215
ZA 2006006833	A	20080528	ZA 2006-6833	20060816
MX 2006009438	A	20061120	MX 2006-9438	20060817
NO 2006004192	A	20061116	NO 2006-4192	20060915
PRIORITY APPLN. INFO.:			US 2004-545762P	P 20040217
			WO 2005-US4902	W 20050215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, are provided. Methods of administering agonists or antagonists of IL-27 and IL-27 receptor, p28, EBI3, WSX/TCCR, and WSX1/TCCR-gp130 complexes are also provided. Agonists or antagonists include antibodies, monoclonal antibodies, polyclonal antibodies, humanized antibodies, antibody fragments, peptide mimetics, or a detectable label.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
Text References

ACCESSION NUMBER: 2005:729611 CAPLUS
 DOCUMENT NUMBER: 143:206465
 TITLE: Therapeutic and carrier molecules
 INVENTOR(S): Ferrante, Antonio; Rathjen, Deborah Ann
 PATENT ASSIGNEE(S): Peplin Biolipids Pty Ltd, Australia
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2005073164</u>	A1	20050811	<u>WO 2005-AU98</u>	20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>AU 2005209331</u>	A1	20050811	<u>AU 2005-209331</u>	20050128
<u>CA 2554735</u>	A1	20050811	<u>CA 2005-2554735</u>	20050128
<u>EP 1718602</u>	A1	20061108	<u>EP 2005-700130</u>	20050128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
<u>CN 1934072</u>	A	20070321	<u>CN 2005-80008891</u>	20050128
<u>BR 2005007236</u>	A	20070626	<u>BR 2005-7236</u>	20050128
<u>JP 2007522118</u>	T	20070809	<u>JP 2006-549788</u>	20050128
<u>US 20090215895</u>	A1	20090827	<u>US 2009-588094</u>	20090507
PRIORITY APPLN. INFO.:			US 2004-540604P	P 20040130
			WO 2005-AU98	W 20050128

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:206465

AB The present invention relates generally to compds. comprising a hydrocarbon chain portion and more particular to compds. comprising chem. derivatizations of the hydrocarbon chain which are useful therapeutic and prophylactic mols. The present invention further provides compds. where the hydrocarbon chain portion is a carrier mol. for functional groups, moieties or agents. The present invention can include naturally including polyunsatd. fatty acids as well as synthetic, modified or derivatized polyunsatd. fatty acids. Furthermore, these polyunsatd. fatty acids can be conjugated to amino acids, peptides or proteins. The compds. of the present invention are particularly useful in the treatment and prophylaxis of a range of conditions including cancers, protein kinase c (PKC)- or NFkB-related- or -assoccd. conditions, cardiovascular conditions, pain, inflammatory conditions, vascular or immunol. conditions such as diabetes, neurol. conditions and infection by a range of viruses or prokaryotic or eukaryotic organisms. The present invention further provides pharmaceutical compns. and methods of medical treatment.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2005:15787 CAPLUS
DOCUMENT NUMBER: 142:92172
TITLE: Cytokine-expressing cellular vaccine combinations for treatment of cancer
INVENTOR(S): Jooss, Karin; Creson, Jennifer; Li, Betty; Prell, Rodney; Aung, Sandra; Moskalenko, Marina Boris; Du, Thomas
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 404,662.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 20050002916</u>	A1	20050106	<u>US 2004-807449</u>	20040324
<u>US 20040197312</u>	A1	20041007	<u>US 2003-404662</u>	20030402

PRIORITY APPLN. INFO.: US 2003-404662 A2 20030402

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The disclosed invention provides improved methods and compns. for treating cancer in a mammal (preferably human) based on the administration of the combination of a cytokine-expressing cellular vaccine and at least one addnl. cancer therapeutic agent or treatment to a patient with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular vaccine or cancer therapeutic agent or treatment as a monotherapy. The examples present the use of cytokine-expressing cellular vaccine (GVAX) in combination with different cancer therapeutic agents in a murine melanoma model (B16F10), renal cell carcinoma (renca), colon carcinoma (CT26), breast carcinoma (4T1), lung cancer (LLC), and fibrosarcoma (3T3).

L11 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2004:589563 CAPLUS
 DOCUMENT NUMBER: 141:134075
 TITLE: Treatment of inflammation with combinations of inhibitors of interleukin 1 and of inhibitors of lymphocyte activation
 INVENTOR(S): Khare, Sanjay Deep
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 203 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2004060911</u>	A2	20040722	<u>WO 2003-US41378</u>	20031224
<u>WO 2004060911</u>	A3	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>CA 2511823</u>	A1	20040722	<u>CA 2003-2511823</u>	20031224
<u>AU 2003299971</u>	A1	20040729	<u>AU 2003-299971</u>	20031224
<u>EP 1578782</u>	A2	20050928	<u>EP 2003-800236</u>	20031224
<u>EP 1578782</u>	A3	20051026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
<u>JP 2006517191</u>	T	20060720	<u>JP 2004-565743</u>	20031224
<u>US 20040208874</u>	A1	20041021	<u>US 2003-748112</u>	20031229
<u>MX 200507019</u>	A	20050818	<u>MX 2005-7019</u>	20050627
<u>US 20080279862</u>	A1	20081113	<u>US 2008-143693</u>	20080620
			<u>US 2002-437405P</u>	P 20021230
			<u>WO 2003-US41378</u>	W 20031224
			<u>US 2003-748112</u>	A1 20031229

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 AB Methods for treating inflammation, esp. in autoimmune disease, by preventing lymphocyte activation using combinations of effectors are described. These may include combinations of IL-1 inhibitors and an inhibitor of B cell or T cell activation. The use of the prior art KIN2 fusion protein of interleukin 1 receptor antagonist and Ig Fc to treat inflammation in a collagen-induced arthritis model is demonstrated. The KIN2 fusion protein lessened inflammation when used alone. A fusion protein of CTLA-4 antigen and Ig Fc was ineffective as an inflammation inhibitor when used alone. When the two fusion proteins were used in combination, the effects on the inflammation were longer-lasting than those of KIN2 alone. Similarly, a combination of the CTLA-4 fusion protein and PEGylated tumor necrosis factor receptor 1 was more effective than the receptor alone. Use of viral vectors expressing genes for these proteins in long-term therapy is also demonstrated.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2003:836393 CAPLUS
 DOCUMENT NUMBER: 1391:336932
 TITLE: Human tumor necrosis factor- $\gamma\beta$, receptor DR3 and TR6, antagonists and antibodies for diagnosis, prognosis and treatment of inflammatory bowel diseases
 INVENTOR(S): Yu, Guo-liang; Ni, Jian; Rosen, Craig A.; Zhang, Jun; Wei, Ping
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 173 pp., Cont.-in-part of U.S. Ser. No. 226,294.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 20030198640</u>	A1	20031023	<u>US 2002-310793</u>	20021206
<u>WO 9614328</u>	A1	19960517	<u>WO 1994-US12880</u>	19941107
W: AU, CA, CN, JP, KR, NZ, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
<u>JP 2002223781</u>	A	20020813	<u>JP 2001-337585</u>	19941107
<u>US 20030027284</u>	A1	20030206	<u>US 1998-131237</u>	19980807
<u>US 6599719</u>	B2	20030729		
<u>US 20020090683</u>	A1	20020711	<u>US 1999-246129</u>	19990208
<u>US 6824767</u>	B2	20041130		
<u>US 20020150534</u>	A1	20020107	<u>US 2001-899059</u>	20010706
<u>US 7597886</u>	B2	20091006		
<u>US 20030129189</u>	A1	20030710	<u>US 2002-226294</u>	20020823
			<u>WO 1994-US12880</u>	A2 19941107
			<u>US 1995-461246</u>	B2 19950605
			<u>US 1998-5020</u>	B2 19980109
			<u>US 1998-74047P</u>	P 19980209
			<u>US 1998-131237</u>	A2 19980807
			<u>US 1999-246129</u>	A2 19990208
			<u>US 1999-131963P</u>	P 19990430
			<u>US 1999-132227P</u>	P 19990503
			<u>US 1999-134067P</u>	P 19990513
			<u>US 2000-180908P</u>	P 20000208
			<u>US 2000-559290</u>	B2 20000427
			<u>US 2000-216879P</u>	P 20000707
			<u>US 2001-278449P</u>	P 20010326
			<u>US 2001-899059</u>	A2 20010706
			<u>US 2001-314381P</u>	P 20010824
			<u>US 2001-336695P</u>	P 20011207
			<u>US 2002-226294</u>	A2 20020823
			<u>JP 1996-515265</u>	A3 19941107
			<u>WO 2000-US11689</u>	A2 20000428

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses methods for detection, diagnosis, prevention, treatment, and/or amelioration of inflammatory bowel diseases and disorders using TNF- $\gamma\beta$ and its receptors DR3 and TR6. In particular the invention encompasses methods of using TNF- $\gamma\beta$,

DR3 and TR6 polypeptides, as well as antibodies, and antagonists thereto, in the diagnosis, prognosis and treatment of ulcerative colitis and/or Crohn's disease. Methods of screening for antagonists of the TNF- $\gamma\beta$ polypeptide, together with therapeutic uses of such antagonists are also disclosed.

L11 ANSWER 11 OF 18 CAPIUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2003:390790 CAPIUS
 DOCUMENT NUMBER: 138:400393
 TITLE: T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions
 INVENTOR(S): Weinberg, Andrew D.; Vandenbergk, Arthur A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,759,546.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 6566082</u>	B1	20030520	<u>US 1995-469633</u>	19950606
<u>US 5759546</u>	A	19980602	<u>US 1994-192480</u>	19940204
<u>WO 9521251</u>	A1	19950810	<u>WO 1995-GB237</u>	19950206
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TG				
<u>AU 9891341</u>	A	19990114	<u>AU 1998-91341</u>	19981104
<u>AU 9891342</u>	A	19990121	<u>AU 1998-91342</u>	19981104
<u>AU 781082</u>	B2	20050505	<u>AU 2001-19731</u>	20010213
<u>AU 782568</u>	B2	20050811	<u>AU 2001-79325</u>	20011010
<u>JP 2007045832</u>	A	20070222	<u>JP 2006-248393</u>	20060913
<u>PRIORITY APPLN. INFO.:</u>				
			<u>US 1994-192480</u>	A2 19940204
			<u>WO 1995-GB237</u>	A 19950206
			<u>AU 1995-15835</u>	A3 19950206
			<u>JP 1995-520474</u>	A3 19950206
			<u>AU 1998-91341</u>	A3 19981104
			<u>AU 1998-91342</u>	A3 19981104

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The OX-40 antigen is characterized and claimed together with variants and derivs. thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells (without affecting the non-activated T cells) in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic mol. (such as ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including multiple sclerosis, rheumatoid arthritis, sarcoidosis, and autoimmune uveitis as well as inflammatory bowel disease and graft-vs.-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all

the diseases mentioned above.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (9 CITINGS)
 REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

[Full Text](#) [Citing References](#)

ACCESSION NUMBER: 2003:133790 CAPLUS
 DOCUMENT NUMBER: 1381:168828
 TITLE: Cytokine receptor-activating agent and co-stimulatory molecule-activating agent for prevention or treatment of cancer, inflammatory disorders or infectious diseases
 INVENTOR(S): Chen, Shu-Hsia; Pan, Ping-Yan; Woo, Savio L. C.
 USA
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 735,296.
 SOURCE: CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 20030035790</u>	A1	20030220	<u>US 2002-165643</u>	20020607
<u>PRIORITY APPLN. INFO.:</u>			<u>US 1999-115992P</u>	P 19990115
			<u>US 2000-735296</u>	A2 20000114

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to compns. comprising compds. which augment activated immune cells, such as T-cells, dendritic cells and natural killer ("NK") cells, and methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising the administration of said compns. to said subject. In particular, the present invention relates to methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising administrating to said subject one or more compds. that activate one or more cytokine receptors and one or more compds. that activate one or more co-stimulatory mols. expressed by activated immune cells. The present invention also relates to compns. and kits comprising a compd. that activates one or more cytokine receptors and a compd. that activates one or more co-stimulatory mols. expressed by activated immune cells.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L11 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

[Full Text](#) [Citing References](#)

ACCESSION NUMBER: 2002:793447 CAPLUS
 DOCUMENT NUMBER: 137:304813
 TITLE: Modulators of hedgehog signaling pathway for treatment of T-cell-mediated diseases
 INVENTOR(S): Lamb, Jonathan Robert; Hoyne, Gerard Francis; Dallman, Margaret Jane; Champion, Brian Robert
 PATENT ASSIGNEE(S): Lorantis Limited, UK
 SOURCE: PCT Int. Appl., 154 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2002080952</u>	A2	20021017	<u>WO 2002-GB1666</u>	20020409
<u>WO 2002080952</u>	A3	20040108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>AU 2002247847</u>	A1	20021021	<u>AU 2002-247847</u>	20020409
<u>EP 1401469</u>	A2	20040331	<u>EP 2002-716928</u>	20020409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
<u>JP 2004534743</u>	T	20041118	<u>JP 2002-578991</u>	20020409
<u>US 20040126359</u>	A1	20040701	<u>US 2003-682230</u>	20031009
<u>PRIORITY APPLN. INFO.:</u>			<u>GB 2001-8872</u>	A 20010409
			<u>GB 2001-8873</u>	A 20010409
			<u>WO 2002-GB1666</u>	W 20020409

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Use of a modulator of a Hedgehog signaling pathway, or a modulator of a pathway which is a target of the Hedgehog signaling pathway in the prepn. of a medicament for treatment of a disease or disorder assocd. with a T-cell mediated disease or disorder.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2001:884232 CAPLUS
 DOCUMENT NUMBER: 136:149820
 TITLE: Augmentation versus inhibition: effects of conjunctival OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
 AUTHOR(S): Kjaergaard, Jorgen; Peng, Liaomin; Cohen, Peter A.; Drazba, Judith A.; Weinberg, Andrew D.; Shu, Suyu
 CORPORATE SOURCE: Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
 SOURCE: Journal of Immunology (2001), 167(11), 6669-6677
 CODEN: JOIMAA; ISSN: 0022-1767
 PUBLISHER: American Association of Immunologists
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Therapeutic efficacy of adoptive immunotherapy of malignancies is proportional to the no. of effector T cells transferred. Traditionally, exogenous IL-2 treatment has been used to promote the survival and

function of transferred cells. Recently, we described the therapeutic effects of *in vivo* ligation of the costimulatory receptor, OX-40R, on activated T cells during early tumor growth. In this study, we examined the effects of IL-2 and OX-40R mAb on adoptive immunotherapy of advanced tumors. For treatment of 10-day 3-methylcholanthrene 205 pulmonary metastases, systemic transfer of 50×10^6 activated tumor-draining lymph node T cells resulted in >99% redn. of metastatic nodules. With either IL-2 or OX-40R mAb conjunctinal treatment, only 20×10^6 cells were required. Advanced 10-day 3-methylcholanthrene 205 intracranial tumors could be cured by the transfer of 15×10^6 L-selectinlow T cells derived from draining lymph nodes. In this situation, IL-2 administration inhibited therapeutic effects of the transferred cells. By contrast, 5×10^6 T cells were sufficient to cure all mice if OX-40R mAb was administered. Studies on trafficking of systemically transferred T cells revealed that IL-2, but not OX-40R mAb, impeded tumor infiltration by T cells. Tumor regression required participation of both CD4 and CD8 T cells. Because only CD4 T cells expressed OX-40R at cell transfer, direct CD4 T cell activation is possible. Alternatively, OX-40R might be up-regulated on transferred T cells at the tumor site, rendering them reactive to the mAb. Our study suggests OX-40R mAb to be a reagent of choice to augment T cell adoptive immunotherapy in clin. trials.

OS.CITING REF COUNT: 44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS RECORD (44 CITINGS)
 REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2001:777015 CAPLUS
 DOCUMENT NUMBER: 135:329667
 TITLE: Adult T-cell leukemia (ATL)
 AUTHOR(S): Uchiyama, Takashi
 CORPORATE SOURCE: Grad. Sch. Med., Kyoto Univ., Japan
 SOURCE: Nippon Naika Gakkai Zasshi (2001), 90(9), 1865-1871
 CODEN: NNGAAS; ISSN: 0021-5384
 PUBLISHER: Nippon Naika Gakkai
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: Japanese
 AB A review with refs., on recent progress in studies on the mechanism and treatment of HTLV-I (human T cell leukemia virus type I)-caused adult T-cell leukemia, discussing clin. features, *in vivo* proliferation mechanism of ATL cells, roles of OX40/gp34 (OX40 ligand) in *in vivo* proliferation of ATL cells, and therapeutic approach to ATL.

L11 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2001:265459 CAPLUS
 DOCUMENT NUMBER: 134:290751
 TITLE: Recombinant single-chain receptor antagonist proteins and their use in treatment of inflammatory disorders
 INVENTOR(S): Halkier, Torben; Schambye, Hans Thalsgard; Okkels, Jens Sigurd; Andersen, Kim Vilborg; Nissen, Torben Laugesgaard; Soni, Bobby; Jeppesen, Claus Bekker; Van Den Hazel, Bart
 PATENT ASSIGNEE(S): Maxygen Aps, Den.
 SOURCE: PCT Int. Appl., 123 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2001025277</u>	A1	20010412	<u>WO 2000-DK563</u>	20001006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GL, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>EP 1226173</u>	A1	20020731	<u>EP 2000-965860</u>	20001006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
<u>US 20040014948</u>	A1	20040122	<u>US 2003-444691</u>	20030523
PRIORITY APPN. INFO.:			<u>DK 1999-1438</u>	A 19991007
			<u>DK 1999-1855</u>	A 19991223
			<u>DK 2000-1119</u>	A 20000720
			<u>US 1999-160820P</u>	P 19991021
			<u>US 2000-174655P</u>	P 20000106
			<u>US 2000-225723P</u>	P 20000816
			<u>US 2000-684720</u>	Bl 20001006
			<u>WO 2000-DK563</u>	W 20001006

AB The invention relates to a single-chain oligomeric protein antagonist which binds to an extracellular ligand-binding domain of a cellular receptor of a type requiring binding of an oligomeric ligand to two or more receptor subunits to be activated, the protein comprising at least two, typically structurally homologous, receptor-binding sites of which at least one is capable of binding to a ligand-binding domain of the cellular receptor and at least one is incapable of effectively binding to a ligand-binding domain of the cellular receptor, whereby the single-chain oligomeric protein is capable of binding to the receptor, but incapable of activating the receptor; as well as to nucleotide sequences encoding such single-chain oligomeric proteins, expression vectors comprising such a nucleotide sequence, recombinant host cells comprising such a nucleotide sequence or expression vector, methods for producing the nucleotide sequences and proteins, pharmaceutical compns. comprising the single-chain oligomeric protein, and use of the single-chain oligomeric protein for the prodn. of medicaments and in therapy. A preferred single-chain antagonist according to the invention is a TNF- α antagonist. Thus, a single-chain TNF- α protein comprising of 3 human TNF- α chains connected by linker peptides was produced with *Saccharomyces cerevisiae* and shown to be an agonist of the TNF- α receptor. The same TNF- α trimer contg. Y87R mutations in the first and third copies of TNF- α was also prep'd. This was shown to be a partial TNF- α agonist and a competitive antagonist of the TNF- α receptor.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD

(9 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 1999:549381 CAPIUS
 DOCUMENT NUMBER: 1311:156919
 TITLE: Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
 INVENTOR(S): Weinberg, Andrew D.
 PATENT ASSIGNEE(S): Sisters of Providence In Oregon, USA
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9942585</u>	A1	19990826	<u>WO 1999-US390B</u>	19990223
W: AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>CA 2321161</u>	A1	19990826	<u>CA 1999-2321161</u>	19990223
<u>AU 9928739</u>	A	19990906	<u>AU 1999-28739</u>	19990223
<u>EP 1060247</u>	A1	20001220	<u>EP 1999-909562</u>	19990223
<u>EP 1060247</u>	B1	20000910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
<u>JP 2002504334</u>	T	20020212	<u>JP 2000-532525</u>	19990223
<u>AP 1261</u>	A	20040319	<u>AP 2000-1903</u>	19990223
<u>AT 408011</u>	T	20080915	<u>AT 1999-909562</u>	19990223
<u>EP 1997893</u>	A1	20081203	<u>EP 2008-15510</u>	19990223
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
<u>PT 1060247</u>	E	20081222	<u>PT 1999-909562</u>	19990223
<u>ES 2315008</u>	T3	20090316	<u>ES 1999-909562</u>	19990223
<u>MX 2000008176</u>	A	20020311	<u>MX 2000-8176</u>	20000821
<u>AU 2002302070</u>	A1	20030320	<u>AU 2002-302070</u>	20021120
<u>AU 2002302070</u>	B2	20071115		
<u>PRIORITY APPLN. INFO.:</u>				
			<u>US 1998-28716</u>	A 19980224
			<u>AU 1999-28739</u>	A3 19990223
			<u>EP 1999-909562</u>	A3 19990223
			<u>WO 1999-US390B</u>	W 19990223

AB Comps. and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed. The compn. administered to the mammal comprises a purified OX-40 receptor binding agent and a pharmaceutically acceptable carrier, wherein said compn. is administered to the mammal such that the OX-40 receptor binding agent is presented to T-cells of the mammal during or shortly after priming of the T-cells by the antigen. The OX-40 receptor binding agent may comprise an OX-40 ligand (a member of the tumor necrosis factor superfamily) or anti-OX-40 antibodies. Engagement of the OX-40 receptor on CD4+ T-cells esp. during, or shortly after, priming of such cells by antigen, can result in an increased response of the CD4+ T-cells to that antigen, and the elevated response to that antigen is maintained for a period of time substantially longer than in the absence of such an engagement. As a result of such engagement, the resistance of an animal

to disease is markedly increased with improved T-cell recognition of antigens presented by infectious agents, such as bacteria and viruses, as well as tumor cells. Such compns. and methods can be used in immunization and cancer treatment. Human OX-40 ligand:Ig fusion protein is an example of a protein applicable to the present invention that can be used in human clin. trials and can stimulate human T cells.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
Text References

ACCESSION NUMBER: 1995:916524 CAPLUS
 DOCUMENT NUMBER: 123:312224
 ORIGINAL REFERENCE NO.: 123:55959a,55962a
 TITLE: **OX-40 antigen** of T lymphocyte for use in diagnosis and **treatment** of T cell-mediated conditions
 INVENTOR(S): Weinberg, Andrew Dale; Vandenberg, Arthur Allen
 PATENT ASSIGNEE(S): Cantab Pharmaceuticals Research Ltd., UK
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9521251</u>	A1	19950810	<u>WO 1995-GB237</u>	19950206
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>US 5759546</u>	A	19980602	<u>US 1994-192480</u>	19940204
<u>CA 2182685</u>	A1	19950810	<u>CA 1995-2182685</u>	19950206
<u>AU 9515835</u>	A	19950821	<u>AU 1995-15835</u>	19950206
<u>EP 742823</u>	A1	19961120	<u>EP 1995-907738</u>	19950206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
<u>JP 09509053</u>	T	19970916	<u>JP 1995-520474</u>	19950206
<u>US 6566082</u>	B1	20030520	<u>US 1995-469633</u>	19950606
<u>AU 9891341</u>	A	19990114	<u>AU 1998-91341</u>	19981104
<u>AU 9891342</u>	A	19990121	<u>AU 1998-91342</u>	19981104
<u>AU 781082</u>	B2	20050505	<u>AU 2001-19731</u>	20010213
<u>AU 782568</u>	B2	20050811	<u>AU 2001-79325</u>	20011010
<u>JP 2007045832</u>	A	20070722	<u>JP 2006-248393</u>	20060913
<u>PRIORITY APPLN. INFO.:</u>				
			<u>US 1994-192480</u>	A 19940204
			<u>AU 1995-15835</u>	A3 19950206
			<u>JP 1995-520474</u>	A3 19950206
			<u>WO 1995-GB237</u>	W 19950206
			<u>AU 1998-91341</u>	A3 19981104
			<u>AU 1998-91342</u>	A3 19981104

AB T lymphocyte **OX-40 antigen** and binding agent (e.g. antibody) for the **antigen** are provided for diagnosis and **treatment** of T cell-mediated diseases. Examples of such use include a method for the selective depletion of activated CD4+ T-cells *in vivo* by using immunotoxins

comprising an OX-40 antibody conjugated to a cytotoxic mol. (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including multiple sclerosis, rheumatoid arthritis, sarcoidosis, and autoimmune uveitis as well as inflammatory bowel disease and graft-vs.-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with the transplantation reaction.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

=> immunogen same Pos
L16 0 IMMUNOGEN SAME POS

 => immunogen (s) fos
L17 1 IMMUNOGEN (S) FOS

 => DNA vaccine (s) fos
L18 7 DNA VACCINE (S) FOS

 => Trial (s) DNA vaccine
L19 395 TRIAL (S) DNA VACCINE

 => antigen (s) L19
L20 23 ANTIGEN (S) L19

 => D L18 IBIB ABS 1-7

L18 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2005:347184 CAPLUS
 DOCUMENT NUMBER: 142:409700
 TITLE: DNA vaccines against tumor growth
 INVENTOR(S): Luo, Yunping; Xiang, Rong; Reisfeld, Ralph A.
 PATENT ASSIGNEE(S): The Scripps Research Institute, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXDD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2005035777</u>	A1	20050421	<u>WO 2004-US33137</u>	20041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MD, MR, NE, SN, TD, TG				
<u>US 20070110717</u>	A1	20070517	<u>US 2006-574752</u>	20060406
<u>US 7569552</u>	B2	20090804		

US 20100136058	A1	20100603	US 2009-462496	20090804
<u>PRIORITY APPLN. INFO.:</u>			US 2003-509457P	P 20031008
			WO 2004-US33137	W 20041007
			US 2006-574752	A1 20060406

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The authors disclose DNA vaccines suitable for eliciting an immune response against cancer cells. The vaccines comprise a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated *Salmonella typhimurium*, particularly a doubly attenuated aroA-dam⁻ *S. typhimurium*. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2005:328835 CAPLUS
 DOCUMENT NUMBER: 142:409367
 TITLE: A DNA Vaccine Targeting Fos-Related Antigen 1 Enhanced by IL-18 Induces Long-lived T-Cell Memory against Tumor Recurrence
 AUTHOR(S): Luo, Yunping; Zhou, He; Mizutani, Masato; Mizutani, Noriko; Liu, Cheng; Xiang, Rong; Reisfeld, Ralph A.
 CORPORATE SOURCE: Department of Immunology, Scripps Research Institute, La Jolla, CA, USA
 SOURCE: Cancer Research (2005), 65(8), 3419-3427
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A novel vaccination strategy induced specific CD8+ T cell-mediated immunity that eradicated spontaneous and exptl. pulmonary cancer metastases in syngeneic mice and was also effective in a therapeutic setting of established breast cancer metastases. This was achieved by targeting transcription factor Fos-related antigen 1(Fra-1), overexpressed by many tumor cells, with an ubiquitinated DNA vaccine against Fra-1, coexpressing secretory IL-18. Insight into the immunological mechanisms involved was provided by adoptive transfer of T lymphocytes from successfully immunized BALB/c mice to syngeneic severe combined immunodeficient (SCID) mice. Specifically, long-lived T memory cells were maintained dormant in nonlymphoid tissues by IL-18 in the absence of tumor antigen. Importantly, a second tumor cell challenge of these SCID mice restored both, robust tumor-specific cytotoxicity and long-lived T-cell memory, capable of eradicating established pulmonary cancer metastases, suggesting that this vaccine could be effective against tumor recurrence.

OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2004:1022267 CAPLUS

DOCUMENT NUMBER: 142:238041
 TITLE: DNA Vaccines Suppress Angiogenesis and Protect Against Growth of Breast Cancer Metastases
 AUTHOR(S): Mizutani, N.; Luo, Y.; Mizutani, M.; Reisfeld, R. A.; Xiang, R.
 CORPORATE SOURCE: The Scripps Research Institute, La Jolla, CA, 92037, USA
 SOURCE: Breast Disease (2004), 20, 81-91
 CODEN: BRDIE5; ISSN: 0888-6008
 PUBLISHER: IOS Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review. Two novel oral DNA-based vaccines provide immune protection against breast cancer in mouse model systems. These vaccines are delivered by attenuated *Salmonella typhimurium* to secondary lymphoid organs and are directed against novel targets such as transcription factor Fos-related antigen 1 (Fra-1) and endoglin (CD105). Both vaccines elicit suppression of angiogenesis in the breast tumor vasculature and break peripheral tolerance by eliciting potent cell-mediated protective immunity against these tumor self-antigens resulting in effective suppression of breast tumor growth and metastasis.
 OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
 REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2004:286197 CAPLUS
 DOCUMENT NUMBER: 141:138646
 TITLE: DNA Vaccines Designed to Inhibit Tumor Growth by Suppression of Angiogenesis
 AUTHOR(S): Reisfeld, Ralph A.; Niethammer, A. G.; Luo, Y.; Xiang, R.
 CORPORATE SOURCE: The Scripps Research Institute, La Jolla, CA, USA
 SOURCE: International Archives of Allergy and Immunology (2004), 133(3), 295-304
 CODEN: IAAIEG; ISSN: 1018-2438
 PUBLISHER: S. Karger AG
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. The development of new blood vessels, i.e. angiogenesis, is a rate-limiting step in the development of tumors since tumor growth is generally limited to 1-2 mm³ in the absence of a blood supply. Thus, the inhibition of tumor growth by attacking the tumor's vascular supply offers a primary target for antiangiogenic intervention by DNA-based vaccines. Here, we describe two novel orally delivered DNA vaccines which suppress tumor angiogenesis and induce a robust cell-mediated immune response that provides for long-lived protection against melanoma, colon, breast and non-small-cell lung carcinoma in mouse model systems. These vaccines, which are delivered by attenuated *Salmonella typhimurium* to secondary lymphoid organs, are directed against such targets as vascular endothelial growth factor receptor 2 (FLK-1) and transcription factor Fos-related antigen 1 (Fra-1). Both vaccines break peripheral T cell tolerance against these self-antigens and induce a robust T cell-mediated immune response leading to suppression of tumor angiogenesis and resulting in effective suppression of tumor growth and metastases. Such research efforts may open up new possibilities for the rational design of future DNA vaccines effective for the prevention and treatment of cancer.

OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2003:588164 CAPLUS
 DOCUMENT NUMBER: 139:178433
 TITLE: Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine
 AUTHOR(S): Luo, Yunping; Zhou, He; Mizutani, Masato; Mizutani, Noriko; Reisfeld, Ralph A.; Xiang, Rong
 CORPORATE SOURCE: Department of Immunology, The Scripps Research Institute, La Jolla, CA, 92037, USA
 SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2003), 100(15), 8850-8855
 CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Protection against breast cancer was achieved with a **DNA vaccine** against murine transcription factor **Fos**-related antigen 1, which is overexpressed in aggressively proliferating D2F2 murine breast carcinoma. Growth of primary s.c. tumor and dissemination of pulmonary metastases was markedly suppressed by this oral **DNA vaccine**, carried by attenuated *Salmonella typhimurium*, encoding murine **Fos**-related antigen 1, fused with mutant polyubiquitin, and contrantransformed with secretory murine IL-18. The life span of 60% of vaccinated mice was tripled in the absence of detectable tumor growth after lethal tumor cell challenge. Immunological mechanisms involved activation of T, natural killer, and dendritic cells, as indicated by up-regulation of their activation markers and costimulatory mols. Markedly increased specific target cell lysis was mediated by both MHC class I-restricted CD8+ T cells and natural killer cells isolated from splenocytes of vaccinated mice, including a significant release of proinflammatory cytokines IFN- γ and IL-2. Importantly, fluorescence anal. of fibroblast growth factor 2 and tumor cell-induced vessel growth in Matrigel plugs demonstrated marked suppression of angiogenesis only in vaccinated animals. Taken together, this multifunctional DNA vaccine proved effective in protecting against growth and metastases of breast cancer by combining the action of immune effector cells with suppression of tumor angiogenesis.

OS.CITING REF COUNT: 50 THERE ARE 50 CAPLUS RECORDS THAT CITE THIS RECORD (51 CITINGS)
 REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2005:266919 BIOSIS
 DOCUMENT NUMBER: PREV200510053751
 TITLE: A **DNA vaccine** targeting **Fos**-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
 AUTHOR(S): Luo, Yunping; Zhou, He; Mizutani, Masato; Mizutani, Noriko; Liu, Cheng; Xiang, Rong; Reisfeld, Ralph A. [Reprint Author]
 CORPORATE SOURCE: Scripps Res Inst, Dept Immunol, R218, IMM13, 10550 N Torrey

Pines Rd, La Jolla, CA 92037 USA

reisfeld@scripps.edu

SOURCE: Cancer Research, (APR 15 2005) Vol. 65, No. 8, pp.

3419-3427.

CODEN: CNREAB. ISSN: 0008-5472.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 21 Jul 2005

Last Updated on STN: 21 Jul 2005

AB A novel vaccination strategy induced specific CWB(+) T cell-mediated immunity that eradicated spontaneous and experimental pulmonary cancer metastases in syngeneic mice and was also effective in a therapeutic setting of established breast cancer metastases. This was achieved by targeting transcription factor Fos-related antigen 1(Fra-1), overexpressed by many tumor cells, with an ubiquitinated DNA vaccine against Fra-1, coexpressing secretory IL-18. Insight into the immunologic mechanisms involved was provided by adoptive transfer of T lymphocytes from successfully immunized BALB/c mice to syngeneic severe combined immunodeficient (SCID) mice. Specifically, long-lived T memory cells were maintained dormant in nonlymphoid tissues by IL-18 in the absence of tumor antigen. Importantly, a second tumor cell challenge of these SCID mice restored both, robust tumor-specific cytotoxicity and long-lived T-cell memory, capable of eradicating established pulmonary cancer metastases, suggesting that this vaccine could be effective against tumor recurrence.

L18 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2003:478104 BIOSIS

DOCUMENT NUMBER: PREV200300478104

TITLE: Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine.

AUTHOR(S): Luo, Yunping; Zhou, He; Mizutani, Masato; Mizutani, Noriko; Reisfeld, Ralph A.; Xiang, Rong [Reprint Author]

CORPORATE SOURCE: Department of Immunology, Scripps Research Institute, La Jolla, CA, 92037, USA
rxiang@scripps.edu

SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (July 22 2003) Vol. 100, No. 15, pp. 8850-8855. print.
 ISSN: 0027-8424 (ISSN print).

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 15 Oct 2003
 Last Updated on STN: 15 Oct 2003

AB Protection against breast cancer was achieved with a DNA vaccine against murine transcription factor Fos-related antigen 1, which is overexpressed in aggressively proliferating D2F2 murine breast carcinoma. Growth of primary s.c. tumor and dissemination of pulmonary metastases was markedly suppressed by this oral DNA vaccine, carried by attenuated *Salmonella typhimurium*, encoding murine Fos-related antigen 1, fused with mutant polyubiquitin, and cotransformed with secretory murine IL-18. The life span of 60% of vaccinated mice was tripled in the absence of detectable tumor growth after lethal tumor cell challenge. Immunological mechanisms involved activation of T, natural killer, and dendritic cells, as indicated by up-regulation of their activation markers and costimulatory molecules. Markedly increased specific target cell lysis was mediated by both MHC class I-restricted CD8+ T cells and natural killer cells isolated from splenocytes of vaccinated mice, including a significant release of proinflammatory cytokines IFN-gamma and IL-2.

Importantly, fluorescence analysis of fibroblast growth factor 2 and tumor cell-induced vessel growth in Matrigel plugs demonstrated marked suppression of angiogenesis only in vaccinated animals. Taken together, this multi-functional DNA vaccine proved effective in protecting against growth and metastases of breast cancer by combining the action of immune effector cells with suppression of tumor angiogenesis.

-> D L20 IBIB ABS 1-23

L20 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2010:078637 CAPLUS
 TITLE: DNA vaccines for the treatment of prostate cancer
 AUTHOR(S): Alam, Sheeba; McNeel, Douglas G.
 CORPORATE SOURCE: Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA
 SOURCE: Expert Review of Vaccines (2010), 9(7), 731-745
 CODEN: ERVXAX; ISSN: 1476-0584
 PUBLISHER: Expert Reviews Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB Prostate cancer is a significant public health problem, and the most commonly diagnosed cancer in the USA. The long natural history of prostate cancer, the presence of a serum biomarker that can be used to detect very early recurrences, and the previous identification of multiple potential tissue-specific target antigens are all features that make this disease suitable for the development of anti-tumor vaccines. To date, many anti-tumor vaccines have entered clin. testing for patients with prostate cancer, and some have demonstrated clin. benefit. DNA vaccines represent one vaccine approach that has been evaluated in multiple preclin. models and clin. trials. The safety, specificity for the target antigen, ease of manufg. and ease of incorporating other immune-modulating approaches make DNA vaccines particularly relevant for future development. This article focuses on **DNA vaccines** specifically in the context of prostate cancer treatment, focusing on **antigens** targeted in preclin. models, recent clin. **trials** and efforts to improve the potency of these vaccines.
 REFERENCE COUNT: 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L20 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2010:453256 CAPLUS
 DOCUMENT NUMBER: 153:59723
 TITLE: DNA vaccines: developing new strategies against cancer
 AUTHOR(S): Fioretti, Daniela; Iurescia, Sandra; Fazio, Vito Michele; Rinaldi, Monica
 CORPORATE SOURCE: Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Rome, 00133, Italy
 SOURCE: Journal of Biomedicine and Biotechnology (2010) No pp. given
 CODEN: JBBQAJ; ISSN: 1110-7251
 URL: <http://downloads.hindawi.com/journals/jbb/2010/174378.pdf>
 PUBLISHER: Hindawi Publishing Corp.

DOCUMENT TYPE: Journal; General Review; (online computer file)
 LANGUAGE: English

AB A review. Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clin. trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clin. trials combines the first phase with the second, saving both time and money. It is clear from the results obtained in clin. trials that such **DNA vaccines** require much improvement in **antigen** expression and delivery methods to make them sufficiently effective in the clinic. Similarly, it is clear that addnl. strategies are required to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technol. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory mols., safe routes of administration, prime-boost regimen and strategies to break the immunosuppressive networks mechanisms adopted by malignant cells to prevent immune cell function. Combined or single strategies to enhance the efficacy and immunogenicity of DNA vaccines are applied in completed and ongoing clin. trials, where the safety and tolerability of the DNA platform are substantiated. In this review on DNA vaccines, salient aspects on this topic going from basic research to the clinic are evaluated. Some representative DNA cancer vaccine studies are also discussed.

REFERENCE COUNT: 149 THERE ARE 149 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L20 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2009:1190632 CAPLUS
 DOCUMENT NUMBER: 152:546148
 TITLE: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
 AUTHOR(S): McNeel, Douglas G.; Dunphy, Edward J.; Davies, James G.; Frye, Thomas P.; Johnson, Laura E.; Staab, Mary Jane; Horvath, Dorothea L.; Straus, Jane; Alberti, Dona; Marnocha, Rebecca; Liu, Glenn; Eickhoff, Jens C.; Wilding, George
 CORPORATE SOURCE: University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA
 SOURCE: Journal of Clinical Oncology (2009), 27(25), 4047-4054
 CODEN: JCONDN; ISSN: 0732-183X
 PUBLISHER: American Society of Clinical Oncology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Purpose: Prostatic acid phosphatase (PAP) is a prostate tumor antigen. We have previously demonstrated that a DNA vaccine encoding PAP can elicit antigen-specific CD8+ T cells in rodents. We report here the results of a phase I/IIa trial conducted with a DNA vaccine encoding human PAP in patients with stage D0 prostate cancer. Patients and Methods: Twenty-two patients were treated in a dose-escalation trial with 100 µg, 500 µg, or 1,500 µg plasmid DNA, coadministered intradermally with 200 µg granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant, six times at 14-day intervals. All patients were obsd. for 1 yr after treatment. Results: No significant adverse events were obsd. Three (14%) of 22 patients developed PAP-specific IFN γ -secreting CD8+

T-cells immediately after the treatment course, as detd. by enzyme-linked immunospot. Nine (41 %) of 22 patients developed PAP-specific CD4+ and/or CD8+ T-cell proliferation. Antibody responses to PAP were not detected. Overall, the prostate-specific antigen (PSA) doubling time was obsd. to increase from a median 6.5 mo pretreatment to 8.5 mo on-treatment ($P = .033$), and 9.3 mo in the 1-yr post-treatment period ($P = .054$). Conclusion: The demonstration that a **DNA vaccine** encoding PAP is safe, elicits an **antigen-specific T-cell response**, and may be assocd. with an increased PSA doubling time suggests that a multi-institutional phase II **trial** designed to evaluate clin. efficacy is warranted.

OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2008:1078606 CAPLUS
 DOCUMENT NUMBER: 150:420535
 TITLE: A DNA vaccine for multiple sclerosis
 AUTHOR(S): Garren, Hideki
 CORPORATE SOURCE: Department of Neurology and Neurological Sciences,
 Stanford University, Stanford, CA, USA
 SOURCE: Expert Opinion on Biological Therapy (2008), 8(10),
 1539-1550
 CODEN: EOBT2; ISSN: 1471-2598
 PUBLISHER: Informa Healthcare
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review. Background: Multiple sclerosis (MS) is a disease in which safety is of paramount importance when developing a potential therapeutic. Antigen-specific treatments provide a method for achieving efficacy while maintaining safety. **DNA vaccines** are one such form of treatment that have been tested in clin. **trials**. Objective: To det. if a **DNA vaccine** is a viable method of **antigen-specific treatment** of MS. Results/conclusion: Phase I and II **trials** of BHT-3009, a **DNA vaccine** encoding myelin basic protein, demonstrated that it was safe, well-tolerated, and caused **antigen-specific immune tolerance**. BHT-3009 showed efficacy in reducing brain lesion activity as well as clin. relapses in patients that were immunol. active at baseline. BHT-3009 is a promising therapy in development for MS, and may prove to be one of the first antigen-specific treatments for this disease.
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2008:1030371 CAPLUS
 DOCUMENT NUMBER: 150:175847
 TITLE: The "A, B and C" of Her-2 DNA vaccine development
 AUTHOR(S): Wei, Wei-Zen; Jacob, Jennifer; Radkevich-Brown, Olga;
 Whittington, Paula; Kong, Yi-chi M.
 CORPORATE SOURCE: Karmanos Cancer Institute and Department of Immunology
 and Microbiology, Wayne State University, Detroit, MI,
 48201, USA
 SOURCE: Cancer Immunology Immunotherapy (2008), 57(11),

1711-1717

CODEN: CIIMDN; ISSN: 0340-7004

PUBLISHER:

Springer

DOCUMENT TYPE:

Journal; General Review

LANGUAGE:

English

AB A review. The development of Her-2 DNA vaccine has progressed through three phases that can be categorized as phase "A": the pursuit of Her-2 as a tumor-assocd. "antigen", phase "B": tilting the "balance" between tumor immunity and autoimmunity and phase "C": the on-going "clin. trials". In phase "A", a panel of human Erbb2-2 or Her-2 plasmids were constructed to encode non-transforming Her-2 derivs. The immunogenicity and anti-tumor activity of Her-2 DNA vaccines were tested in human Her-2 transgenic mice with or without the depletion of regulatory T cells (Tregs). However, Treg depletion or other immune modulating regimens may increase the risk of autoimmunity. In phase "B", the balance between tumor immunity and autoimmunity was assessed by monitoring the development of exptl. autoimmune thyroiditis (EAT). To test the efficacy of Her-2 DNA vaccines in cancer patients, clin. trials have been initiated in phase "C". Significant anti-Her-2 and anti-tumor activity was obsd. When Her-2 transgenic mice were electro-vaccinated after Treg depletion. Susceptibility to EAT was also enhanced by Treg depletion and there was mutual amplification between Her-2 immunity and EAT development. Although Tregs regulate both EAT and Her-2 immunity, their effector mechanisms may differ. It may be possible to amplify tumor immunity with improved strategies that can bypass undue autoimmunity. Crit. information will be revealed in the next decade to expedite the development of cancer vaccines.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	2008:307551 CAPLUS
DOCUMENT NUMBER:	148:583434
TITLE:	DNA vaccination for prostate cancer
AUTHOR(S):	Roos, Anna-Karin; King, Alan; Pisa, Pavel
CORPORATE SOURCE:	Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Stockholm, Swed.
SOURCE:	Methods in Molecular Biology (Totowa, NJ, United States) (2008), 423(Electroporation Protocols), 463-472
PUBLISHER:	CODEN: MMBIED; ISSN: 1064-3745
DOCUMENT TYPE:	Humania Press Inc.
LANGUAGE:	Journal; General Review

AB A review. DNA-based cancer vaccines have been used successfully in mice to induce cytotoxic T lymphocytes (CTLs) specific for prostate antigens. Translation of a prostate-specific antigen (PSA) DNA vaccine into a phase I clin. trial demonstrated that PSA-specific immune responses could be induced but at a significantly lower level compared with those in mice. To enhance the efficacy of DNA vaccination against prostate cancer, we have explored and optimized intradermal electroporation as an effective way of delivering a PSA DNA vaccine. The results demonstrated that intradermal DNA vaccination using low amts. of DNA, followed by two sets of elec. pulses of different length and voltage, effectively induced PSA-specific T cells. Here we describe in detail how to perform intradermal DNA electroporation to induce high gene expression in skin

and, more important, how to induce and analyze PSA-specific T cell responses.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2007:842719 CAPLUS
 DOCUMENT NUMBER: 147:446136
 TITLE: Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer
 Hällermalm, K.; Johansson, S.; Brave, A.; Ek, M.; Engström, G.; Boberg, A.; Gudmundsdotter, L.; Blomberg, P.; Mellstedt, H.; Stout, R.; Liu, M. A.; Wahren, B.
 AUTHOR(S):
 CORPORATE SOURCE: Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet and Swedish Institute for Infectious Disease Control, Tualatin, OR, USA
 SOURCE: Scandinavian Journal of Immunology (2007), 66(1), 43-51
 CODEN: SJIMAX; ISSN: 0300-9475
 PUBLISHER: Blackwell Publishing Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB In prepn. for a clin. trial in patients diagnosed with colorectal cancer, a vaccination strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP-produced plasmid DNA vaccine, CEA66, encoding a truncated form of the tumor-assocd. antigen, CEA. The GMP-produced CEA DNA vaccine was also evaluated for toxicity. Repeated intradermal administration of the GMP-produced vaccine using a novel needle-free jet injection device (Biojector) induced robust CD4 and CD8 T-cell responses in mice, and did not result in any vaccine-related toxicity. In a heterologous DNA prime/protein boost setting, cellular immune responses were of higher magnitude in animals primed with CEA66 DNA than in animals receiving repeated doses of recombinant CEA protein. These responses were further enhanced if recombinant murine granulocyte-macrophage colony-stimulating factor was given as an adjuvant prior to vaccination. In contrast to repeated administration of recombinant CEA protein as a single modality vaccine, the heterologous CEA66 DNA prime/rCEA boost vaccination strategy resulted in a qual. broader immune response, and supports clin. testing of this vaccination regimen in humans.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full Citing
 Text References

ACCESSION NUMBER: 2007:770366 CAPLUS
 DOCUMENT NUMBER: 147:196818
 TITLE: A vaccine to prevent transmission of human malaria: a long way to travel on a dusty and often bumpy road
 AUTHOR(S): Kumar, Nirbhay
 CORPORATE SOURCE: Johns Hopkins Malaria Research Institute, Molecular Microbiology and Immunology, Bloomberg School of

PUBLIC SOURCE: Public Health, Johns Hopkins University, Baltimore, MD, 21205, USA
 PUBLISHER: Current Science (2007), 92(11), 1535-1544
 DOCUMENT TYPE: CODEN: CUSCAM; ISSN: 0011-3891
 LANGUAGE: Current Science Association
 English

AB A review. The goal for an effective malaria transmission-blocking vaccine (TBV) is to induce immunity against the stages of the parasite that infect mosquitoes so that malaria transmission can be reduced or halted. Malaria transmission is generally spatially confined to an infectious source, thus a TBV used in a community can effectively suppress malaria transmission to others. Antibodies induced by TBVs target antigens on the surface of sexual and mosquito midgut stages of the malaria parasite and antibodies interfere with the development of the parasites in the midgut of the mosquito. Proteins synthesized in the gametocytes (pre-fertilization antigens, in *Plasmodium falciparum*: Pf230 and Pf48/45) and in the zygotes-ookinetes (post-fertilization antigens, in *P. falciparum*: Pf25 and Pf28) represent some of the key target antigens for the development of TBVs. All the four proteins contain multiple cysteine-rich sequences and the epitopes recognized by transmission-blocking antibodies are redm.-sensitive conformational in nature. The inability to express properly folded proteins has frustrated a protein-based TBV development approach and DNA-based vaccine constructs were envisaged to overcome the conformational problem in recombinant proteins. Indeed studies in mice and monkeys have firmly established the value of DNA-based TBV approach. Although immunogenic in larger animals, delivery of DNA-based TBVs needs to be further optimized to elicit a strong and long lasting functional immune response. This **DNA vaccine** platform can also facilitate evaluation of a cocktail of pre- and post-fertilization **antigens** in pre-clin. setting prior to the development of an ideal and effective TBV for clin. **trials** in human volunteers.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2005:603844 CAPLUS
 DOCUMENT NUMBER: 144:348557
 TITLE: Carriers for the delivery of a vaccine against respiratory syncytial virus
 AUTHOR(S): Cranage, Martin; Taylor, Geraldine
 CORPORATE SOURCE: Centre for Infection, Division of Cellular and Molecular Medicine, University of London, London, SW17 ORE, UK
 SOURCE: Expert Opinion on Biological Therapy (2005), 5(7), 939-952
 PUBLISHER: CODEN: EOBTA2; ISSN: 1471-2598
 DOCUMENT TYPE: Ashley Publications Ltd.
 LANGUAGE: Journal; General Review
 English
 AB A review. Respiratory syncytial virus (RSV) is a major cause of bronchiolitis and pneumonia in young children and the elderly. Despite its clin. importance, there is no licensed vaccine available at present. Vaccine development has been hampered by observations of increased pathol. after RSV infection in infants vaccinated with formalin-inactivated RSV; incomplete immunity following natural infection; and the need to be

effective during the neonatal period when levels of maternal antibody are high. Four categories of RSV vaccine carriers - live-attenuated RSVs, recombinant vectors expressing the protective **antigens** of RSV, **DNA vaccines** and subunit vaccines - have been evaluated in animal models and/or clin. **trials**. So far, studies with live-attenuated virus vaccines highlight the need to improve immunogenicity while maintaining a suitable level of attenuation. Studies with recombinant vectors, DNA and subunit vaccines illustrate the pivotal nature of the vaccine carrier in detg. the balance between immune-mediated protection against infection and the induction of immune-mediated pulmonary pathol.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References
ACCESSION NUMBER:	2005:385528 CAPLUS
DOCUMENT NUMBER:	142:409267
TITLE:	Tumor antigens for cancer immunotherapy: Therapeutic potential of xenogeneic DNA vaccines
AUTHOR(S):	Srinivasan, Roopa; Wolchok, Jedd D.
CORPORATE SOURCE:	Division of Tumor Immunology, Dept. of Research, CancerVax Corporation, Carlsbad, CA, 92008, USA
SOURCE:	Journal of Translational Medicine (2004), 2, No pp. given
CODEN:	JTMOBV; ISSN: 1479-5876
URL:	http://www.translational-medicine.com/content/pdf/1479-5876-2-12.pdf
PUBLISHER:	BioMed Central Ltd.
DOCUMENT TYPE:	Journal; General Review; (online computer file)
LANGUAGE:	English
AB	A review. Preclin. animal studies have convincingly demonstrated that tumor immunity to self antigens can be actively induced and can translate into an effective anti-tumor response. Several of these observations are being tested in clin. trials. Immunization with xenogeneic DNA is an attractive approach to treat cancer since it generates T cell and antibody responses. When working in concert, these mechanisms may improve the efficacy of vaccines. The use of xenogeneic DNA in overcoming immune tolerance has been promising not only in inbred mice with transplanted tumors but also in outbred canines, which present with spontaneous tumors, as in the case of human. Use of this strategy also overcomes limitations seen in other types of cancer vaccines. Immunization against defined tumor antigens using a xenogeneic DNA vaccine is currently being tested in early phase clin. trials for the treatment of melanoma and prostate cancers, with proposed trials for breast cancer and Non-Hodgkin's Lymphoma.
REFERENCE COUNT:	97 THERE ARE 97 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References
ACCESSION NUMBER:	2005:113893 CAPLUS
DOCUMENT NUMBER:	142:196372
TITLE:	Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1

AUTHOR(S): Nordstroem, Eva K. L.; Forsell, Mattias N. E.; Barnfield, Christina; Bonin, Elvior; Hanke, Tomas; Sundstroem, Magnus; Karlsson, Gunilla B.; Liljestroem, Peter

CORPORATE SOURCE: Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, S-171 77, Swed.

SOURCE: Journal of General Virology (2005), 86(2), 349-354

CODEN: JGVIAY; ISSN: 0022-1317

PUBLISHER: Society for General Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clin. trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clin. studies.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2000:672733 CAPLUS

DOCUMENT NUMBER: 134:264623

TITLE: DNA vaccines against B-cell tumors

AUTHOR(S): Stevenson, Freda K.; Zhu, Delin; Spellerberg, Myfanwy; King, Catherine A.; Sahota, Surinder S.; Rice, Jason; Thompsett, Andrew R.; Hamblin, Terry J.

CORPORATE SOURCE: Molecular Immunology Group Tenovus Laboratory, Southampton University Hospital Trust, Southampton, UK

SOURCE: Cancer Vaccines and Immunotherapy (2000), 21B-236.

Editor(s): Stern, Peter L.; Beverley, Peter C. L.; Carroll, Miles W. Cambridge University Press: Cambridge, UK.

CODEN: 69AKYN

DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

AB A review with 55 refs. Topics discussed include B-cell malignancies and the clin. need for vaccines, idiotypic determinants as B-cell tumor antigens, DNA vaccines, and clin. trials of DNA vaccines.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2000:549736 CAPLUS

DOCUMENT NUMBER: 134:176875

TITLE: DNA vaccination against cancer antigens

AUTHOR(S): Stevenson, F. K.; Zhu, D.; Spellerberg, M. B.; Rice, J.; King, C. A.; Thompsett, A. R.; Sahota, S. S.;

CORPORATE SOURCE: Hamblin, T. J.
 Molecular Immunology Group, Tenovus Laboratory,
 Southampton University Hospital, Southampton, SO9 4XY,
 UK
 SOURCE: Ernst Schering Research Foundation Workshop (2000),
 30 ('Therapeutic Vaccination Strategies'), 119-136
 PUBLISHER: Springer-Verlag
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 32 refs. Topics discussed include a general overview of DNA vaccines, idiotypic Ig of B cell malignancies, idiotypic DNA vaccines against lymphoma, DNA fusion gene vaccines against alternative tumor antigens, idiotypic DNA fusion gene vaccines against secreted Ig of multiple myeloma, effect of pre-existing anti-fragment C (anti-FrC) antibody, clin. trial of DNA vaccines, and DNA vaccines against intracellular tumor antigens.
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	1997:726095 CAPLUS
DOCUMENT NUMBER:	128:2681
ORIGINAL REFERENCE NO.:	128:595a,598a
TITLE:	Toward clinical trials of DNA vaccines against malaria
AUTHOR(S):	Hoffman, Stephen L.; Doolan, Denise L.; Sedegah, Martha; Wang, Ruobing; Scheller, Libia F.; Kumar, Anita; Weiss, Walter R.; Le, Thong P.; Klinman, Dennis M.; Hobart, Peter; Norman, Jon A.; Hedstrom, Richard C.
CORPORATE SOURCE:	Malaria Program, Naval Med. Res. Inst., Bethesda, MD, USA
SOURCE:	Immunology and Cell Biology (1997), 75(4), 376-381
PUBLISHER:	Blackwell
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English
AB	A review with 65 refs. In mid 1997 the first malaria DNA vaccine has entered clin. trials. This single gene DNA vaccine encoding the Plasmodium falciparum circumsporozoite protein (PfCSP) will be studied for safety and immunogenicity. If these criteria are met, a multi-gene DNA vaccine designed to induce protective CD8+ T cell responses against P. falciparum infected hepatocytes will be subsequently assessed for safety, immunogenicity, and capacity to protect immunized volunteers against exptl. challenge with P. falciparum sporozoites. Herein, the authors discuss the rationale and exptl. foundation for these anticipated P. falciparum DNA vaccine trials.
OS.CITING REF COUNT:	22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)
REFERENCE COUNT:	65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 15 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full Text	Citing References
-----------	-------------------

STN

ACCESSION NUMBER: 2010:328250 BIOSIS
 DOCUMENT NUMBER: PREV201000328250
 TITLE: DNA Vaccines: Developing New Strategies against Cancer.
 AUTHOR(S): Fioretti, Daniela; Iurescia, Sandra; Fazio, Vito Michele;
 Rinaldi, Monica [Reprint Author]
 CORPORATE SOURCE: CNR, Dept Med, Inst Neurobiol and Mol Med, Via Fosso
 Cavaliere 100, I-00133 Rome, Italy
monica.rinaldi@artov.inmm.cnr.it
 SOURCE: Journal of Biomedicine & Biotechnology, (2010) pp. Article
 No.: 174378.
 ISSN: 1110-7243.
 DOCUMENT TYPE: Article
 General Review; (Literature Review)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 9 Jun 2010
 Last Updated on STN: 9 Jun 2010

AB Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical trials combines the first phase with the second, saving both time and money. It is clear from the results obtained in clinical trials that such **DNA vaccines** require much improvement in **antigen** expression and delivery methods to make them sufficiently effective in the clinic. Similarly, it is clear that additional strategies are required to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technology. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe routes of administration, prime-boost regimen and strategies to break the immunosuppressive networks mechanisms adopted by malignant cells to prevent immune cell function. Combined or single strategies to enhance the efficacy and immunogenicity of DNA vaccines are applied in completed and ongoing clinical trials, where the safety and tolerability of the DNA platform are substantiated. In this review on DNA vaccines, salient aspects on this topic going from basic research to the clinic are evaluated. Some representative DNA cancer vaccine studies are also discussed.

L20 ANSWER 16 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full	Citing
Text	References
STN	

ACCESSION NUMBER: 2008:387184 BIOSIS
 DOCUMENT NUMBER: PREV200800387183
 TITLE: DNA vaccination for prostate cancer.
 AUTHOR(S): Roos, Anna-Karin [Reprint Author]; King, Alan; Pisa, Pavel
 CORPORATE SOURCE: Karolinska Inst, Canc Ctr Karolinska R8 01, Dept Pathol and
 Oncol, Stockholm, Sweden
 SOURCE: Li, S [Editor]. Methods in Molecular Biology, (2008) pp.
 463-472. Methods in Molecular Biology.
 Publisher: HUMANA PRESS INC, 999 RIVERVIEW DR, STE 208,
 TOTOWA, NJ 07512-1165 USA. Series: METHODS IN MOLECULAR
 BIOLOGY.
 ISSN: 1064-3745. ISBN: 978-1-58829-877-5 (II).
 DOCUMENT TYPE: Book; (Book Chapter)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Jul 2008
 Last Updated on STN: 16 Jul 2008

AB DNA-based cancer vaccines have been used successfully in mice to induce cytotoxic T lymphocytes (CTLs) specific for prostate antigens. Translation of a prostate-specific antigen (PSA) DNA vaccine into a phase I clinical trial demonstrated that PSA-specific immune responses could be induced but at a significantly lower level compared with those in mice. To enhance the efficacy of DNA vaccination against prostate cancer, we have explored and optimized intradermal electroporation as an effective way of delivering a PSA DNA vaccine. The results demonstrated that intradermal DNA vaccination using low amounts of DNA, followed by two sets of electrical pulses of different length and voltage, effectively induced PSA-specific T cells. Here we describe in detail how to perform intradermal DNA electroporation to induce high gene expression in skin and, more important, how to induce and analyze PSA-specific T cell responses.

L20 ANSWER 17 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full Citing
 Text References

STN
 ACCESSION NUMBER: 2008:199957 BIOSIS
 DOCUMENT NUMBER: PREV200800193803
 TITLE: **DNA vaccine trials** using 3 blood stage **antigens** of Plasmodium vivax Korean isolates.
 AUTHOR(S): Shin, Eun-Hee [Reprint Author]; Kim, Hyo-Jin; Lee, Jo Woon Yi; Lee, Jin-Ju; Choi, Jong-Yil
 CORPORATE SOURCE: Seoul Natl Univ, Coll Med, Seoul 151, South Korea
 SOURCE: American Journal of Tropical Medicine and Hygiene, (NOV 2007) Vol. 77, No. 5, Suppl. S, pp. 163.
 Meeting Info.: 56th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene. Philadelphia, PA, USA. November 04 -08, 2007. Amer Soc Trop Med & Hyg.
 CODEN: AJTHAB. ISSN: 0002-9637.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 19 Mar 2008
 Last Updated on STN: 19 Mar 2008

L20 ANSWER 18 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full Citing
 Text References

STN
 ACCESSION NUMBER: 2008:5477 BIOSIS
 DOCUMENT NUMBER: PREV20080004390
 TITLE: A vaccine to prevent transmission of human malaria: A long way to travel on a dusty and often bumpy road.
 AUTHOR(S): Kumar, Nirbhay [Reprint Author]
 CORPORATE SOURCE: Johns Hopkins Med Inst, Bloomberg Sch Publ Hlth, Johns Hopkins Malaria Res Ctr, 615 N Wolfe St, Baltimore, MD 21205 USA
nkumar@jhsph.edu
 SOURCE: Current Science (Bangalore), (JUN 10 2007) Vol. 92, No. 11, pp. 1535-1544.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 12 Dec 2007
 Last Updated on STN: 12 Dec 2007

AB The goal for an effective malaria transmission-blocking vaccine (TBV) is

to induce immunity against the stages of the parasite that infect mosquitoes so that malaria transmission can be reduced or halted. Malaria transmission is generally spatially confined to an infectious source, thus a TBV used in a community can effectively suppress malaria transmission to others. Antibodies induced by TBVs target antigens on the surface of sexual and mosquito midgut stages of the malaria parasite and antibodies interfere with the development of the parasites in the midgut of the mosquito. Proteins synthesized in the gametocytes (pre-fertilization antigens, in *Plasmodium falciparum*: Pfs230 and Pfs48/45) and in the zygotes-ookinetes (post-fertilization antigens, in *P. falciparum*: Pfs25 and Pfs28) represent some of the key target antigens for the development of TBVs. All the four proteins contain multiple cysteine-rich sequences and the epitopes recognized by transmission-blocking antibodies are reduction-sensitive conformational in nature. The inability to express properly folded proteins has frustrated a protein-based TBV development approach and DNA-based vaccine constructs were envisaged to overcome the conformational problem in recombinant proteins. Indeed studies in mice and monkeys have firmly established the value of DNA-based TBV approach. Although immunogenic in larger animals, delivery of DNA-based TBVs needs to be further optimized to elicit a strong and long lasting functional immune response. This **DNA vaccine** platform can also facilitate evaluation of a cocktail of pre- and post-fertilization **antigens** in pre-clinical setting prior to the development of an ideal and effective TBV for clinical **trials** in human volunteers.

L20 ANSWER 19 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full Citong
 Text References

STN

ACCESSION NUMBER: 2007:466754 BIOSIS
 DOCUMENT NUMBER: PREV200700472517
 TITLE: Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer.
 AUTHOR(S): Hallermalm, K. [Reprint Author]; Johansson, S.; Bräve, A.; Ek, M.; Engstrom, G.; Boberg, A.; Gudmundsdotter, L.; Blomberg, P.; Mellstedt, H.; Stout, R.; Liu, M. A.; Wahren, B.
 CORPORATE SOURCE: Swedish Inst Infect Dis Control, Dept Virol Immunol and Vaccinol, SE-17182 Solna, Sweden
kristian.hallermalm@smi.ki.se
 SOURCE: Scandinavian Journal of Immunology, (JUL 2007) Vol. 66, No. 1, pp. 43-51.
 CODEN: SJIMAX. ISSN: 0300-9475.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 5 Sep 2007
 Last Updated on STN: 5 Sep 2007
 AB In preparation for a clinical **trial** in patients diagnosed with colorectal cancer, a vaccination strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP-produced plasmid **DNA vaccine**, CEA66, encoding a truncated form of the tumour-associated antigen, CEA. The GMP-produced CEA DNA vaccine was also evaluated for toxicity. Repeated intradermal administration of the GMP-produced vaccine using a novel needle-free jet injection device (Biojector) induced robust CD4 and CD8 T-cell responses in mice, and did not result in any vaccine-related toxicity. In a heterologous DNA prime/protein boost setting, cellular immune responses were of higher magnitude in animals primed with CEA66 DNA than in animals receiving repeated doses of recombinant CEA protein. These responses were further enhanced if recombinant murine granulocyte-macrophage colony-stimulating factor was

given as an adjuvant prior to vaccination. In contrast to repeated administration of recombinant CEA protein as a single modality vaccine, the heterologous CEA66 DNA prime/rCEA boost vaccination strategy resulted in a qualitatively broader immune response, and supports clinical testing of this vaccination regimen in humans.

L20 ANSWER 20 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full Text	Citing References
-----------	-------------------

STN

ACCESSION NUMBER: 2005:479124 BIOSIS
 DOCUMENT NUMBER: PREV200510271028
 TITLE: DNA immunization against melanoma antigens enhances tumor immunity in mice following sub-lethal irradiation and immune reconstitution.
 AUTHOR(S): Diab, Adi [Reprint Author]; Hubbard, Vanessa M.; Cohen, Adam; Huggins, Deonka; Kochman, Adam; Guevarra, Jose A.; Engelhorn, Manuel; Wolchok, Jedd D.; van den Brink, Marcel; Houghton, Alan N.; Perales, Miguel-Angel
 CORPORATE SOURCE: Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
 SOURCE: Blood, (NOV 16 2004) Vol. 104, No. 11, Part 1, pp. 835A.
 Meeting Info.: 46th Annual Meeting of the American-Society-of-Hematology. San Diego, CA, USA. December 04 -07, 2004. Amer Soc Hematol.
 CODEN: BLOOAW. ISSN: 0006-4971.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; (Meeting Poster)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Nov 2005
 Last Updated on STN: 16 Nov 2005
 AB The development of successful cancer vaccines is contingent on the ability to induce effective anti-tumor immunity against self-antigens that do not typically elicit immunity. We are working on strategies to overcome immunologic tolerance/ignorance to cancer through the use of gene products closely related to self-**antigens**, including xenogeneic DNA and mutated DNA, and have initiated clinical **trials** of **DNA vaccines** in patients with advanced melanoma or prostate cancer. Recent studies have demonstrated that homeostasis-driven T-cell proliferation in the reconstituted lymphodepleted host could enhance the efficacy of whole-cell tumor vaccines. We hypothesized that immunization of sub-lethally irradiated and immune reconstituted mice against specific tumor antigens could increase anti-tumor immunity. B6 mice were irradiated with 600 cGy and immediately reconstituted with 30 x 10⁶ syngeneic splenocytes. Weekly DNA immunization using either human tyrosinase-related protein (TRP)-2 DNA (xenogeneic melanoma differentiation antigen (MDA) or Opt-Tyrp1 DNA (a mutated MDA, which has been optimized for CD8 epitopes), was begun on day 1. We have found that: (1) by day 14 after irradiation and reconstitution, recipients have considerable numbers of splenic T cells, including de novo generated donor T cells, which suggests that vaccination aimed at T cells might be feasible; (2) DNA immunization against a single tumor antigen can provide protection from a tumor challenge that is significantly greater than that observed in immunized non-irradiated hosts (Figure); (3) DNA immunization induces higher levels of tumor-specific CD8(+) T cells in the irradiated and reconstituted recipients (detected by intracellular cytokine flow cytometry assay); and (4) the effects of DNA immunization after lymphodepletion with immune reconstitution on both tumor-free survival and CD8(+) T cell responses have been validated for two different DNA vaccine strategies (TRP-2 DNA and Opt-Tyrp1 DNA). These results demonstrate that DNA immunization following

sub-lethal irradiation and immune reconstitution can induce potent anti-tumor effects. Furthermore, they provide a strong rationale for the development of novel therapeutic strategies that combine lymphodepletion with immune reconstitution and DNA immunization in human clinical trials. [GRAPHICS]

L20 ANSWER 21 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full Text	Citing References
-----------	-------------------

STN

ACCESSION NUMBER: 2005:476372 BIOSIS
 DOCUMENT NUMBER: PREV200510268276
 TITLE: DNA immunization against melanoma antigens enhances tumor immunity in mouse models of allogeneic hematopoietic stem cell transplantation (HSCT).
 AUTHOR(S): Diab, Adi [Reprint Author]; Perales, Miquel-Angel; Cohen, Adam; Hubbard, Vanessa M.; Eng, Jeff; Huggins, Deonka; Engelhorn, Manuel; Guevarra, Jose A.; Alpdogan, Onder; Wolchok, Jedd D.; Kochman, Adam; Houghton, Alan N.; van den Brink, Marcel
 CORPORATE SOURCE: Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
 SOURCE: Blood, (NOV 16 2004) Vol. 104, No. 11, Part 1, pp. 90A-91A.
 Meeting Info.: 46th Annual Meeting of the American-Society-of-Hematology. San Diego, CA, USA.
 December 04 -07, 2004. Amer Soc Hematol.
 CODEN: BLOOA. ISSN: 0006-4971.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Nov 2005
 Last Updated on STN: 16 Nov 2005

AB Allogeneic HSCT is an important therapy with curative potential for a variety of malignant diseases, including leukemias, lymphomas and some solid tumors. Despite significant progress in reducing treatment-related mortality, malignant relapse remains a major problem. We are developing **DNA vaccines** that encode gene products closely related to **self-antigens**, including xenogeneic DNA and mutated DNA, and have initiated clinical **trials of DNA vaccines** in patients with advanced melanoma or prostate cancer. Using the B16 mouse melanoma model, we have shown that immunization with human TRP-2 DNA (xenogeneic melanoma differentiation antigen-MDA) or Opt-Tytpl DNA (a mutated MDA related to TRP-2, which we have optimized for CD8 epitopes), can induce tumor protection, including against established tumors. We hypothesized that immunization of allogeneic HSCT recipients (or their donors) against specific tumor antigens could decrease the risk of relapse without enhancing graft-versus-host disease (GVHD). In an MHC-matched minor antigen-mismatched mouse HSCT model (LP into B6), we found that: (1) by day 28 after transplant, recipients of an allogeneic T-cell depleted (TCD)-HSCT have considerable numbers of splenic T cells, including de novo generated donor T cells, which suggests that vaccination aimed at T cells might be feasible; (2) post-HSCT DNA immunization against a single tumor antigen can provide protection from a tumor challenge that is comparable to that observed with a whole cell vaccine (B16-GM-CSF) and significantly greater than HSCT alone; (3) DNA immunization post-HSCT can induce tumor-specific CD8(+) T cells of donor origin (detected by ELISPOT or intracellular cytokine flow cytometry assay); (4) the combination of donor leukocyte infusion (DLI) and post-HSCT DNA immunization further enhances tumor-free survival (Figure); (5) there is no evidence of GVHD in multiple experiments using a clinical GVHD score to monitor recipients; and (6) the

effects of post-HSCT DNA immunization on both tumor-free survival and CD8(+) T cell responses have been validated for two different DNA vaccine strategies (hTRP-2 + GM-CSF DNA, or Opt-Typr1DNA). These results demonstrate that DNA immunization after allogeneic TCD-HSCT can induce potent anti-tumor effects without the induction of GVHD. This and similar investigations provide a strong rationale for the development of novel therapeutic strategies that combine allogeneic HSCT, post-transplant tumor vaccination and adoptive cell therapy in human clinical trials. [GRAPHICS]

L20 ANSWER 22 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full	Citing
Text	References

STN

ACCESSION NUMBER: 2005:169595 BIOSIS
 DOCUMENT NUMBER: PREV200500170549
 TITLE: Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.
 AUTHOR(S): Nordström, Eva K. L.; Forsell, Mattias N. E.; Barnfield, Christina; Bonin, Eivor; Hanke, Tomas; Sundstrom, Magnus; Karlsson, Gunilla B. [Reprint Author]; Liljestrom, Peter
 CORPORATE SOURCE: Ctr Microbiol and Tumor Biol, Karolinska Inst, S-17177, Stockholm, Sweden
Nilla.Karlsson@mtc.ki.se
 SOURCE: Journal of General Virology, (February 2005) Vol. 86, No. Part 2, pp. 349-354. print.
 ISSN: 0022-1317 (ISSN print).

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 4 May 2005
 Last Updated on STN: 4 May 2005

AB With the human immunodeficiency virus type I (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-Cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTMr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.

L20 ANSWER 23 OF 23 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

Full	Citing
Text	References

STN

ACCESSION NUMBER: 2003:561994 BIOSIS
 DOCUMENT NUMBER: PREV200300562038
 TITLE: DNA vaccines: An active immunization strategy for prostate cancer.
 AUTHOR(S): Wolchok, Jedd D. [Reprint Author]; Gregor, Polly D.; Nordquist, Luke T.; Slovin, Susan F.; Scher, Howard I.
 CORPORATE SOURCE: Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA
 SOURCE: Seminars in Oncology, (October 2003) Vol. 30, No. 5, pp. 659-666. print.

DOCUMENT TYPE: ISSN: 0093-7754 (ISSN print).
 Article
 General Review; (Literature Review)

LANGUAGE: English

ENTRY DATE: Entered STN: 26 Nov 2003
 Last Updated on STN: 26 Nov 2003

-> transcriptional (w) factor

L21 8161 TRANSCRIPTIONAL (W) FACTOR

-> (co-expression) (s) antigen

L22 631 (CO-EXPRESSION) (S) ANTIGEN

-> L21 and L22

L23 1 L21 AND L22

-> D L23 IBIB ABS

L23 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN

Full	Citing
Text	References

ACCESSION NUMBER: 2006183871 BIOSIS
 DOCUMENT NUMBER: PREV200600185983
 TITLE: Differential patterns of transcriptional protein expression may explain functional differences between hematopoietic progenitors derived from human ESC's and fetal hematopoietic tissues.

AUTHOR(S): Shaaban, Aimen F. [Reprint Author]; Golos, Thaddeus G.; Thomson, James A.; Rajesh, Deepika

CORPORATE SOURCE: Univ Wisconsin, Sch Med, Dept Surg Anat and Obstet and Gynecol, Madison, WI USA

SOURCE: Blood, (NOV 16 2005) Vol. 106, No. 11, Part 1, pp. 1007A.
 Meeting Info.: 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA, USA. December 10 -13, 2005. Amer Soc Hematol.

CODEN: BLOAAW. ISSN: 0006-4971.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 15 Mar 2006
 Last Updated on STN: 15 Mar 2006

AB Recent studies suggest that development of human embryoid body-derived hematopoietic progenitor cells (EB-HPC's) mirrors that of primitive yolk sac-derived hematopoietic progenitors (YS-HPC's) in their expression of transcription factors known to be critically associated with hematopoietic development. However, the findings of these studies were limited to molecular characterization of heterogeneous EB cultures rather than analysis of hematopoietic lineage-committed cell subsets. We wondered: 1) if the expression patterns were consistent at the protein level in both bulk EB cultures and subsets of hematopoietic-lineage committed cells; and 2) if these expression patterns differed from those found in definitive HPC's harvested from early fetal hematopoietic tissues. To answer these questions, we compared the intracellular expression of critical transcriptional regulatory proteins from human and rhesus EB-derived HPC's (hEB-HPC's and rEB-HPC's) with hematopoietic progenitors from rhesus fetal liver (rFL-HPC's) and rhesus placental blood HPC's (rPB-HPC's). Rhesus macaque fetal tissue was used in lieu of scarce human fetal tissues. Using multi-color intracellular flow cytometry we correlated the expression of transcriptional proteins (SCL/TAL1, GATA-1, GATA-2, Oct-3/4,

HOXB4} with cell surface determinants of hematopoietic commitment (CD34, CD31, CD45) in hEB-HPC's, rEB-HPC's, rFL-HPC's and rPB-HPC's. Human and rhesus EB16 cells were harvested from identical culture conditions and compared to 0.34 gestation rFL-HPC's and rPB-HPC's. The frequency of CD45+ cells was higher in hEB-HPC's (31%) and rPB-HPC's (46%) compared to rFL-HPC's and rEB-HPC's. A much higher frequency of GATA-1 and HOXB4 expressing cells was seen in both of the fetal cell types when compared to either rhesus or human EB's. Additionally, the frequency of GATA-2 and SCL expressing cells was comparable in all cell types. Lastly, the expression of Oct3/4 was higher in rPB-HPC's and rFL-HPC's when compared to bulk EB cultures. However, analysis of subsets of EB cells expressing hematopoietic **antigens** (CD45, CD34) revealed **co-expression** of Oct-3/4 on both CD45+ and CD34+ cell fractions. From these findings, we conclude: 1) critical differences exist in GATA-1 and HOXB4 expression between HPC's derived from EB cultures and HPC's harvested during early definitive fetal hematopoietic development; and 2) human EB-derived hematopoietic progenitor cells express persistently high levels of Oct-3/4. The differences in the expression of these critical **transcriptional factors** at the protein level may explain the observed functional differences between EB-derived HPC's and definitive HPC's from fetal and adult sources.

->